# EDGAR Filing Document

**Accession Number:** 0000070318
**File Stem:** 0000070318-26-000026
**Filing Date:** 2026-4
**Character Count:** 171270
**Document Hash:** 9f04bf0165723becabcefc3b02d8c75b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000070318-26-000026.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0000070318-26-000026

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 97

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TENET HEALTHCARE CORP
- **CENTRAL INDEX KEY:** 0000070318
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 952557091
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-07293
- **FILM NUMBER:** 26924868

**BUSINESS ADDRESS:**
- **STREET 1:** 14201 DALLAS PARKWAY
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75254
- **BUSINESS PHONE:** 469-893-2200

**MAIL ADDRESS:**
- **STREET 1:** 14201 DALLAS PARKWAY
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75254

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NATIONAL MEDICAL ENTERPRISES INC /NV/
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? thc-20260331

---

| |
|:---|
| **UNITED STATES** |
| **SECURITIES AND EXCHANGE COMMISSION** |
| **Washington, DC 20549** |
| **Form 10-Q**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;🗷 **Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended**<br> **March 31, 2026** |
| **OR** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◻ **Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from**<br>**__________ to** |
| **Commission File Number: 1-7293** |
| **TENET HEALTHCARE CORPORATION** |
| (Exact name of Registrant as specified in its charter) |
| **95-2557091**<br>(IRS Employer Identification No.) |
| **14201 Dallas Parkway** <br>**Dallas, TX 75254**<br>(Address of principal executive offices, including zip code) |
| **(469) 893-2200** <br>(Registrant's telephone number, including area code) |
| **Securities registered pursuant to Section 12(b) of the Act:** |

---

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol** | **Name of each exchange on which registered** |
| Common stock, $0.05 par value | THC | New York Stock Exchange |
| 6.875% Senior Notes due 2031 | THC31 | New York Stock Exchange |

---

---

| |
|:---|
| Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes 🗷 No ◻ |
| Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months. Yes 🗷 No ◻ |
| Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company (each as defined in Exchange Act Rule 12b-2). |

---

Large accelerated filer 🗷 Accelerated filer ◻ Non-accelerated filer ◻

Smaller reporting company ◻ Emerging growth company ◻

---

| |
|:---|
| If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻ |
| Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes ◻ No 🗷 |
| As of April 22, 2026, there were 86,137 shares (in thousands) of the Registrant's common stock outstanding. |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**TENET HEALTHCARE CORPORATION**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **<u>[PART I. FINANCIAL INFORMATION](#i7edabb704b8149fc98557a0e4d1fc5ff_13)</u>** | **<u>[PART I. FINANCIAL INFORMATION](#i7edabb704b8149fc98557a0e4d1fc5ff_13)</u>** | |
| <u>[Item 1.](#i7edabb704b8149fc98557a0e4d1fc5ff_16)</u> | <u>[Financial Statements (Unaudited)](#i7edabb704b8149fc98557a0e4d1fc5ff_16)</u> |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Financial Statements](#i7edabb704b8149fc98557a0e4d1fc5ff_19)</u> | <u>[1](#i7edabb704b8149fc98557a0e4d1fc5ff_16)</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#i7edabb704b8149fc98557a0e4d1fc5ff_31)</u> | <u>[5](#i7edabb704b8149fc98557a0e4d1fc5ff_31)</u> |
| <u>[Item 2.](#i7edabb704b8149fc98557a0e4d1fc5ff_121)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i7edabb704b8149fc98557a0e4d1fc5ff_121)</u> | <u>[21](#i7edabb704b8149fc98557a0e4d1fc5ff_121)</u> |
| <u>[Item 3.](#i7edabb704b8149fc98557a0e4d1fc5ff_205)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i7edabb704b8149fc98557a0e4d1fc5ff_205)</u> | <u>[37](#i7edabb704b8149fc98557a0e4d1fc5ff_205)</u> |
| <u>[Item 4.](#i7edabb704b8149fc98557a0e4d1fc5ff_208)</u> | <u>[Controls and Procedures](#i7edabb704b8149fc98557a0e4d1fc5ff_208)</u> | <u>[38](#i7edabb704b8149fc98557a0e4d1fc5ff_208)</u> |
| **<u>[PART II. OTHER INFORMATION](#i7edabb704b8149fc98557a0e4d1fc5ff_214)</u>** | **<u>[PART II. OTHER INFORMATION](#i7edabb704b8149fc98557a0e4d1fc5ff_214)</u>** |  |
| <u>[Item 1.](#i7edabb704b8149fc98557a0e4d1fc5ff_217)</u> | <u>[Legal Proceedings](#i7edabb704b8149fc98557a0e4d1fc5ff_217)</u> | <u>[39](#i7edabb704b8149fc98557a0e4d1fc5ff_217)</u> |
| <u>[Item 1A.](#i7edabb704b8149fc98557a0e4d1fc5ff_220)</u> | <u>[Risk Factors](#i7edabb704b8149fc98557a0e4d1fc5ff_220)</u> | <u>[39](#i7edabb704b8149fc98557a0e4d1fc5ff_220)</u> |
| <u>[Item 2.](#i7edabb704b8149fc98557a0e4d1fc5ff_223)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i7edabb704b8149fc98557a0e4d1fc5ff_223)</u> | <u>[39](#i7edabb704b8149fc98557a0e4d1fc5ff_223)</u> |
| <u>[Item 5.](#i7edabb704b8149fc98557a0e4d1fc5ff_226)</u> | <u>[Other Information](#i7edabb704b8149fc98557a0e4d1fc5ff_226)</u> | <u>[39](#i7edabb704b8149fc98557a0e4d1fc5ff_226)</u> |
| <u>[Item 6.](#i7edabb704b8149fc98557a0e4d1fc5ff_235)</u> | <u>[Exhibits](#i7edabb704b8149fc98557a0e4d1fc5ff_235)</u> | <u>[40](#i7edabb704b8149fc98557a0e4d1fc5ff_235)</u> |

---

i

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**TENET HEALTHCARE CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**Dollars in Millions, Share Amounts in Thousands**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| **ASSETS** |  |  |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $2967 | $2883 |
| &nbsp;&nbsp;&nbsp;Accounts receivable | 2605 | 2565 |
| &nbsp;&nbsp;&nbsp;Inventories of supplies, at cost | 343 | 348 |
| &nbsp;&nbsp;&nbsp;Assets held for sale | 62 | 62 |
| &nbsp;&nbsp;&nbsp;Other current assets | 2379 | 1991 |
| &nbsp;&nbsp;&nbsp;**Total current assets** | **8356** | **7849** |
| Investments and other assets | 3809 | 2883 |
| Deferred income taxes | 84 | 84 |
| &nbsp;&nbsp;Property and equipment, at cost, less accumulated depreciation and amortization <br>($6,814 at March 31, 2026 and $6,680 at December 31, 2025) | 6251 | 6315 |
| Goodwill | 11387 | 11198 |
| Other intangible assets, at cost, less accumulated amortization ($1,378 at March 31, 2026 and $1,328 at December 31, 2025) | 1316 | 1348 |
| **Total assets** | $**31203** | $**29677** |
| **LIABILITIES AND EQUITY** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | $81 | $79 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 1339 | 1360 |
| &nbsp;&nbsp;&nbsp;Accrued compensation and benefits | 854 | 858 |
| &nbsp;&nbsp;&nbsp;Professional and general liability reserves | 303 | 276 |
| &nbsp;&nbsp;&nbsp;Accrued interest payable | 256 | 81 |
| &nbsp;&nbsp;&nbsp;Income tax payable | 236 |  |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 3083 | 1809 |
| &nbsp;&nbsp;&nbsp;**Total current liabilities** | **6152** | **4463** |
| Long-term debt, net of current portion | 13128 | 13092 |
| Professional and general liability reserves | 938 | 951 |
| Defined benefit plan obligations | 243 | 245 |
| Deferred income taxes | 199 | 240 |
| Other long-term liabilities | 1693 | 1713 |
| **Total liabilities** | **22353** | **20704** |
| Commitments and contingencies |  |  |
| Redeemable noncontrolling interests in equity of consolidated subsidiaries | 2137 | 2956 |
| **Equity:** |  |  |
| &nbsp;&nbsp;&nbsp;**Shareholders' equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.05 par value; authorized 262,500 shares; 159,129 shares issued at March 31, 2026 and 158,612 shares issued at December 31, 2025 | 8 | 8 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 5124 | 4914 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (179) | (181) |
| &nbsp;&nbsp;&nbsp;Retained earnings | 5117 | 4415 |
| &nbsp;&nbsp;&nbsp;Common stock in treasury, at cost, 73,005 shares at March 31, 2026 and 71,660 shares at December 31, 2025 | (5256) | (4936) |
| &nbsp;&nbsp;&nbsp;**Total shareholders' equity** | **4814** | **4220** |
| **Noncontrolling interests** | **1899** | **1797** |
| **Total equity** | **6713** | **6017** |
| **Total liabilities and equity** | $**31203** | $**29677** |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**TENET HEALTHCARE CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**Dollars in Millions, Except Per-Share Amounts**

**(Unaudited)** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Net operating revenues** | $**5368** | $**5223** |
| **Revenue from contract termination** | **413** | **—** |
| **Equity in earnings of unconsolidated affiliates** | **51** | **56** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 2174 | 2119 |
| &nbsp;&nbsp;&nbsp;Supplies | 961 | 907 |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 1122 | 1090 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 229 | 206 |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 24 | 19 |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 27 | 17 |
| &nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities | (1) | (22) |
| **Operating income** | **1296** | **943** |
| &nbsp;&nbsp;&nbsp;Interest expense | (205) | (204) |
| &nbsp;&nbsp;&nbsp;Other non-operating income, net | 41 | 26 |
| **Income before income taxes** | **1132** | **765** |
| Income tax expense | (226) | (143) |
| **Net income** | **906** | **622** |
| &nbsp;&nbsp;&nbsp;Less: Net income available to noncontrolling interests | 204 | 216 |
| **Net income available to Tenet Healthcare Corporation common shareholders** | $**702** | $**406** |
| **Earnings available to Tenet Healthcare Corporation common shareholders:** |  |  |
| &nbsp;&nbsp;&nbsp;Basic earnings per share | $8.09 | $4.31 |
| &nbsp;&nbsp;&nbsp;Diluted earnings per share | $8.01 | $4.27 |
| &nbsp;&nbsp;&nbsp;**Weighted average shares and dilutive securities outstanding (in thousands):** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 86801 | 94242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 87596 | 95019 |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**TENET HEALTHCARE CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME**

**Dollars in Millions**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net income | $906 | $622 |
| Other comprehensive income: |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of net actuarial loss included in other non-operating income, net | 2 | 2 |
| &nbsp;&nbsp;&nbsp;Unrealized loss on debt securities held as available-for-sale | (1) |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments and other | 1 |  |
| **Other comprehensive income before income taxes** | **2** | **2** |
| Income tax expense related to items of other comprehensive income |  |  |
| **Total other comprehensive income, net of tax** | **2** | **2** |
| **Comprehensive net income** | **908** | **624** |
| **Less: Comprehensive income available to noncontrolling interests** | **204** | **216** |
| **Comprehensive income available to Tenet Healthcare Corporation common shareholders** | $**704** | $**408** |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**TENET HEALTHCARE CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**Dollars in Millions**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Net income** | $**906** | $**622** |
| **Adjustments to reconcile net income to net cash provided by operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 229 | 206 |
| &nbsp;&nbsp;&nbsp;Deferred income tax expense (benefit) | (40) | 4 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 25 | 21 |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 24 | 19 |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 27 | 17 |
| &nbsp;&nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities | (1) | (22) |
| &nbsp;&nbsp;&nbsp;Equity in earnings of unconsolidated affiliates, net of distributions received | 29 | 5 |
| &nbsp;&nbsp;&nbsp;Amortization of debt discount and debt issuance costs | 5 | 6 |
| &nbsp;&nbsp;&nbsp;Net gains from the sale of investments and long-lived assets | (1) |  |
| &nbsp;&nbsp;&nbsp;Other items, net | 2 | 2 |
| **Changes in cash from operating assets and liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable | (28) | (69) |
| &nbsp;&nbsp;&nbsp;Inventories and other current assets | 407 | (108) |
| &nbsp;&nbsp;&nbsp;Income taxes | 259 | 132 |
| &nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses and other current liabilities | (145) | 24 |
| &nbsp;&nbsp;&nbsp;Other long-term liabilities |  | (8) |
| **Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements** | **(57)** | **(36)** |
| &nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | **1641** | **815** |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of property and equipment | (180) | (173) |
| &nbsp;&nbsp;&nbsp;Purchases of businesses or joint venture interests, net of cash acquired | (121) | (27) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of facilities and other assets | 2 | 11 |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of marketable securities and long-term investments | 22 | 14 |
| &nbsp;&nbsp;&nbsp;Purchases of marketable securities and long-term investments | (26) | (17) |
| &nbsp;&nbsp;&nbsp;Other items, net | (14) | 5 |
| &nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | **(317)** | **(187)** |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Repayments of borrowings | (33) | (32) |
| &nbsp;&nbsp;&nbsp;Proceeds from borrowings | 14 | 1 |
| &nbsp;&nbsp;&nbsp;Repurchases of common stock | (318) | (348) |
| &nbsp;&nbsp;&nbsp;Distributions paid to noncontrolling interests | (197) | (189) |
| &nbsp;&nbsp;&nbsp;Proceeds from the sale of noncontrolling interests | 6 | 11 |
| &nbsp;&nbsp;&nbsp;Purchases of noncontrolling interests | (549) | (41) |
| &nbsp;&nbsp;&nbsp;Repayments of advances from managed care payers |  | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes paid related to net share settlement, net of proceeds from shares issued under <br>stock-based compensation plans | (86) | (32) |
| &nbsp;&nbsp;&nbsp;Other items, net | (77) | (7) |
| &nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | **(1240)** | **(648)** |
| Net increase (decrease) in cash and cash equivalents | 84 | (20) |
| Cash and cash equivalents at beginning of period | 2883 | 3019 |
| **Cash and cash equivalents at end of period** | $**2967** | $**2999** |
| Supplemental disclosures: |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid, net of capitalized interest | $(24) | $(99) |
| &nbsp;&nbsp;&nbsp;Income tax payments, net | $(8) | $(7) |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**TENET HEALTHCARE CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE 1. BASIS OF PRESENTATION**

**Description of Business and Basis of Presentation**

Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as "Tenet," "we" or "us") is a diversified healthcare services company headquartered in Dallas, Texas. Our expansive, nationwide care delivery network consists of our Hospital Operations and Services ("Hospital Operations") and Ambulatory Care segments. As of March 31, 2026, our Hospital Operations segment was comprised of 50 acute care and specialty hospitals, a network of employed physicians and 132 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency departments and micro-hospitals. Our Ambulatory Care segment is comprised of the operations of USPI Holding Company, Inc. (together with its subsidiaries, "USPI"), which held ownership interests in 541 ambulatory surgery centers and 26 surgical hospitals at March 31, 2026. USPI held noncontrolling interests in 152 of these facilities, which are recorded using the equity method of accounting. In addition, we operate a Global Business Center ("GBC") in the Philippines.

Our Hospital Operations segment also provides revenue cycle management and value-based care services to hospitals and other healthcare facilities, health systems, physician practices, employers and other clients through Conifer Health Solutions, LLC ("Conifer"), which was a wholly owned subsidiary at March 31, 2026. We owned 76.2% of Conifer at December 31, 2025, and the remaining 23.8% was held by Catholic Health Initiatives ("CHI"), now known as CommonSpirit Health. Prior to January 2026, Conifer provided services to certain CHI facilities under an amended and restated master services agreement (the "RCM Agreement"), which was scheduled to end on December 31, 2032. On January 27, 2026, we entered into certain agreements with CHI relating to Conifer (collectively, the "Omnibus Agreement"). Subject to the terms of the Omnibus Agreement, the parties agreed to, among other things: (1) conclude the RCM Agreement by December 31, 2026; (2) CHI's payment to us of an aggregate amount equal to $1.900 billion in annual installments over the next three years; provided that, of such amount, $540 million was satisfied on January 27, 2026 by offsetting the $540 million due to CHI from Conifer as described in the next clause; and (3) the reduction of our redeemable noncontrolling interest balance, and an increase in our additional paid-in capital balance associated with the redemption by Conifer of CHI's minority equity interest in Conifer, in exchange for a payment by Conifer of $540 million, which redemption was effective January 1, 2026.

This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2025 ("Annual Report"). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, dollar amounts presented in our Condensed Consolidated Financial Statements and these accompanying notes are expressed in millions (except per-share amounts), and all share amounts are expressed in thousands.

We adopted the Financial Accounting Standards Board's Accounting Standards Update ("ASU") 2025-10, "Government Grants" ("ASU 2025-10"), effective as of January 1, 2026, using the modified prospective approach. We have elected to apply the cost accumulation approach for grants related to assets. Under this method, we will initially measure the subject asset on the basis of the cost incurred to acquire or construct the asset, less the monetary grant received or expected to be received when the grant meets recognition criteria. The adoption of ASU 2025-10 did not result in a change in our method of accounting for grants related to income, and we will continue to reflect the earnings impact of these grants in other income in our condensed consolidated statements of operations. The adoption of this standard did not have a material impact on our financial statements.

Although our Condensed Consolidated Financial Statements and these related notes are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires us to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

Operating results for the three-month period ended March 31, 2026 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: the impact of the demand for, and availability of, qualified medical personnel on compensation costs; overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; trends in patient accounts receivable collectability and associated implicit price concessions; the impact of cybersecurity incidents on our operations; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to cybersecurity incidents, natural disasters and weather-related occurrences; the potential emergence and effects of future pandemics, epidemics or outbreaks of infectious diseases on our operations, financial condition and liquidity; litigation and investigation costs; fluctuations in the costs associated with our defined contribution retirement plans; acquisitions and dispositions of facilities and other assets; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains (losses) from early extinguishment of debt; and changes in occupancy levels and patient volumes.

Our hospitals and outpatient facilities are subject to various factors that affect our service mix, revenue mix and patient volumes and, thereby, impact our net patient service revenues and results of operations. These factors include, among others: changes in federal and state statutes, regulations and executive orders that effect the healthcare industry directly or indirectly, particularly those impacting government healthcare funding; changes in general economic conditions, including inflation, shortages and outages, whether due to geopolitical conflicts, trade tensions, export control rules, tariffs or other factors; the number of uninsured and underinsured individuals in local communities treated at our facilities; cybersecurity incidents, including those targeting our vendors, and other unanticipated information technology outages; disease hotspots and seasonal cycles of illness; weather-related conditions and natural disasters; physician recruitment, satisfaction, retention and attrition; advances in technology and treatments that reduce length of stay or permit procedures to be performed in an outpatient rather than inpatient setting; local healthcare competitors; utilization pressure by managed care organizations, as well as managed care contract negotiations or terminations; performance data on quality measures and patient satisfaction, as well as pricing for services; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; and changing consumer behavior, including with respect to the timing of elective procedures. These considerations apply to year-to-year comparisons as well.

**Cash and Cash Equivalents**

We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $2.967 billion and $2.883 billion at March 31, 2026 and December 31, 2025, respectively. At March 31, 2026 and December 31, 2025, our book overdrafts were $139 million and $161 million, respectively, which were classified as accounts payable. Also at March 31, 2026 and December 31, 2025, $107 million and $108 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our insurance-related subsidiaries.

At March 31, 2026 and December 31, 2025, we had $44 million and $111 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $36 million and $102 million, respectively, were included in accounts payable.

**Leases**

During the three months ended March 31, 2026 and 2025, we recorded right-of-use assets related to non-cancellable finance leases of $14 million and $18 million, respectively, and related to non-cancellable operating leases of $77 million and $62 million, respectively.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**Goodwill**

The following table presents information on changes in the carrying amount of goodwill for each of our segments:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Hospital Operations:** |  |  |
| &nbsp;&nbsp;&nbsp;Goodwill at beginning of period, net of accumulated impairment losses | $2697 | $2697 |
| &nbsp;&nbsp;&nbsp;Goodwill acquired during the period, net of purchase price allocation adjustments |  |  |
| &nbsp;&nbsp;&nbsp;**Goodwill at end of period, net of accumulated impairment losses** | **2697** | **2697** |
| **Ambulatory Care:** |  |  |
| &nbsp;&nbsp;&nbsp;Goodwill at beginning of period | 8501 | 7994 |
| &nbsp;&nbsp;&nbsp;Goodwill acquired during the period, including purchase price allocation adjustments | 189 | 95 |
| &nbsp;&nbsp;&nbsp;**Goodwill at end of period** | **8690** | **8089** |
| **Total goodwill, net of accumulated impairment losses** | $**11387** | $**10786** |

---

**Other Intangible Assets**

The following table presents information regarding other intangible assets, which were included in the accompanying Condensed Consolidated Balance Sheets:

---

| | | | |
|:---|:---|:---|:---|
| | **Gross <br>Carrying Amount** | **Accumulated<br>Amortization** | **Net Book Value** |
| **At March 31, 2026:** | | | |
| &nbsp;&nbsp;&nbsp;Other intangible assets with finite useful lives: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalized software costs | $1525 | $(1192) | $333 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contracts | 242 | (171) | 71 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 43 | (15) | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets with finite lives | 1810 | (1378) | 432 |
| &nbsp;&nbsp;&nbsp;Other intangible assets with indefinite useful lives: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade names | 105 |  | 105 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contracts | 774 |  | 774 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 5 |  | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets with indefinite lives | 884 |  | 884 |
| &nbsp;&nbsp;&nbsp;**Total other intangible assets, net** | $**2694** | $**(1378)** | $**1316** |
| **At December 31, 2025:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Other intangible assets with finite useful lives: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalized software costs | $1511 | $(1166) | $345 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contracts | 241 | (148) | 93 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 42 | (14) | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets with finite lives | 1794 | (1328) | 466 |
| &nbsp;&nbsp;&nbsp;Other intangible assets with indefinite useful lives: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade names | 105 |  | 105 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contracts | 773 |  | 773 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 4 |  | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets with indefinite lives | 882 |  | 882 |
| &nbsp;&nbsp;&nbsp;**Total other intangible assets, net** | $**2676** | $**(1328)** | $**1348** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

The table below presents our estimated future amortization of intangible assets with finite useful lives at March 31, 2026:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Nine<br>Months<br> Ending** | **Years Ending** | **Years Ending** | **Years Ending** | **Years Ending** | **Later Years** |
| | | | **December 31,** | **December 31,** | **December 31,** | **December 31,** | **Later Years** |
| |<br>**Total** | **2026** | **2027** | **2028** | **2029** | **2030** | **Later Years** |
| Amortization of intangible assets | $432 | $165 | $87 | $67 | $45 | $25 | $43 |

---

We recognized amortization expense of $40 million in the accompanying Condensed Consolidated Statements of Operations during each of the three months ended March 31, 2026 and 2025.

**Other Current Assets**

The principal components of other current assets in the accompanying Condensed Consolidated Balance Sheets are presented below:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Prepaid expenses | $351 | $423 |
| Contract assets | 201 | 188 |
| California provider fee program receivables | 401 | 493 |
| Receivables from other government programs | 468 | 385 |
| Guarantees | 162 | 138 |
| Non-patient receivables | 292 | 224 |
| Current portion of note receivable | 395 |  |
| Other | 109 | 140 |
| **Total other current assets** | $**2379** | $**1991** |

---

Under the terms of the Omnibus Agreement, in January 2026, CHI executed and delivered a $1.360 billion non-interest-bearing promissory note in connection with the early conclusion of the RCM Agreement between Conifer and CHI (the "CHI Note Receivable"). The CHI Note Receivable requires three annual payments of approximately $453 million, with the first two payments due in January 2027 and January 2028 and the final payment, together with any unpaid principal, due in January 2029. Of the CHI Note Receivable's carrying amount, which is recorded at present value, $395 million was included in other current assets and $828 million was included in investments and other assets in the accompanying Condensed Consolidated Balance Sheet at March 31, 2026.

**Investments in Unconsolidated Affiliates**

As of March 31, 2026, we controlled 415 of the facilities in our Ambulatory Care segment and, therefore, consolidated their results. We account for many of the facilities in which our Ambulatory Care segment holds ownership interests (152 of 567 at March 31, 2026), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in our condensed consolidated statements of operations. Summarized financial information for equity method investees is presented in the following table. For investments acquired during the reported periods, amounts in the table include 100% of the investee's results beginning on the date of our acquisition of the investment.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net operating revenues | $882 | $859 |
| Net income | $213 | $215 |
| Net income available to the investees | $122 | $125 |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**NOTE 2. ACCOUNTS RECEIVABLE AND CONTRACT BALANCES**

**Accounts Receivable**

The principal components of accounts receivable are presented in the table below:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Patient accounts receivable | $2470 | $2418 |
| Estimated future recoveries | 135 | 148 |
| Cost reports and settlements payable and valuation allowances |  | (1) |
| **Accounts receivable, net** | $**2605** | $**2565** |

---

**Contract Balances**

Our Hospital Operations segment's contract assets and liabilities primarily derive from: (1) patients receiving ongoing inpatient care from one of our facilities at the end of the reporting period; and (2) timing differences between our performance of revenue cycle management and other contract-based services and the invoicing or receipt of payment for these services. Our Hospital Operations segment's contract assets were included in other current assets or investments and other assets, and its contract liabilities were included in other current liabilities or other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. The following table presents the opening and closing balances of our Hospital Operations segment's contract assets, current and long-term receivables, and current and long-term contract liabilities:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Current<br>Receivables** | **Contract Assets – <br>Unbilled Revenue** | **Long-Term Receivables** | **Contract Liabilities –<br>Current<br>Deferred Revenue** | **Contract Liabilities –<br>Long-Term<br>Deferred Revenue** |
| December 31, 2025 | $26 | $188 | $— | $88 | $13 |
| March 31, 2026 | 480 | 201 | 828 | 1406 | 5 |
| **Increase (decrease)** | $**454** | $**13** | $**828** | $**1318** | $**(8)** |
| December 31, 2024 | $28 | $190 | $— | $80 | $13 |
| March 31, 2025 | 16 | 202 |  | 105 | 13 |
| **Increase (decrease)** | $**(12)** | $**12** | $**—** | $**25** | $**—** |

---

The differences between the balances of our contract assets and liabilities at March 31, 2026 and December 31, 2025 were primarily attributable to the effect of the provisions in the Omnibus Agreement. Our contract balances during this period were also impacted by patients who were receiving inpatient acute care and specialty hospital services as of December 31, 2025, but who were discharged during the three months ended March 31, 2026. The differences between the balances of our contract assets and liabilities at March 31, 2025 and December 31, 2024 primarily related to patients who were receiving inpatient acute care and specialty hospital services as of December 31, 2024, but who were discharged during the three months ended March 31, 2025.

During the three months ended March 31, 2026 and 2025, we recognized revenue totaling $68 million and $54 million, respectively, from our revenue cycle management services that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those contract clients who were billed in advance, changes in estimates related to metric-based services and up-front integration services that are recognized over the service period.

*Contract Costs—*We recognized amortization expense related to deferred contract setup costs of $3 million and $1 million during the three months ended March 31, 2026 and 2025, respectively. At March 31, 2026 and December 31, 2025, unamortized client contract setup costs were $10 million and $13 million, respectively, and were presented as part of investments and other assets in the accompanying Condensed Consolidated Balance Sheets.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**Uninsured and Charity Patient Costs**

The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Estimated costs for: |  |  |
| &nbsp;&nbsp;&nbsp;Uninsured patients | $108 | $114 |
| &nbsp;&nbsp;&nbsp;Charity care patients | 34 | 17 |
| &nbsp;&nbsp;&nbsp;**Total**  | $**142** | $**131** |

---

**NOTE 3. DISPOSITION OF ASSETS AND LIABILITIES**

At both March 31, 2026 and December 31, 2025, our assets classified as held for sale consisted of a building we own in West Palm Beach, Florida. The carrying value of the assets related to this building was $62 million at March 31, 2026 and December 31, 2025.

**NOTE 4. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION**-**RELATED COSTS**

Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility's most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.

We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost-effective structure, such as the establishment of support operations at our GBC, among other things. Certain restructuring and acquisition-related costs are based on estimates. Changes in estimates are recognized as they occur.

During the three months ended March 31, 2026, we recorded impairment and restructuring charges and acquisition-related costs of $24 million, consisting of $14 million of restructuring charges, $7 million of impairment charges and $3 million of acquisition-related transaction costs. Restructuring charges during this period included $6 million of employee severance costs, $4 million of contract and lease termination fees, $3 million related to the transition of various administrative functions to our GBC and $1 million of other restructuring costs. Impairment charges recognized during the three months ended March 31, 2026 primarily related to the write-down of assets associated with Ambulatory Care segment facilities closed during the period.

During the three months ended March 31, 2025, we recorded impairment and restructuring charges and acquisition-related costs of $19 million, consisting of $15 million of restructuring charges and $4 million of acquisition-related transaction costs. Restructuring charges during this period included $7 million of contract and lease termination fees, $3 million of legal costs related to the sale of certain businesses, $3 million related to the transition of various administrative functions to our GBC and $2 million of employee severance costs.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**NOTE 5. LONG-TERM DEBT**

The table below presents our long-term debt included in the accompanying Condensed Consolidated Balance Sheets:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Senior unsecured notes: |  |  |
| &nbsp;&nbsp;&nbsp;6.125% due 2028 | $1750 | $1750 |
| &nbsp;&nbsp;&nbsp;6.875% due 2031 | 362 | 362 |
| &nbsp;&nbsp;&nbsp;6.000% due 2033 | 750 | 750 |
| Senior secured first lien notes: |  |  |
| &nbsp;&nbsp;&nbsp;5.125% due 2027 | 1500 | 1500 |
| &nbsp;&nbsp;&nbsp;4.625% due 2028 | 600 | 600 |
| &nbsp;&nbsp;&nbsp;4.250% due 2029 | 1400 | 1400 |
| &nbsp;&nbsp;&nbsp;4.375% due 2030 | 1450 | 1450 |
| &nbsp;&nbsp;&nbsp;6.125% due 2030 | 2000 | 2000 |
| &nbsp;&nbsp;&nbsp;6.750% due 2031 | 1350 | 1350 |
| &nbsp;&nbsp;&nbsp;5.500% due 2032 | 1500 | 1500 |
| Finance leases, mortgages and other notes | 636 | 603 |
| Unamortized issue costs and note discounts | (89) | (94) |
| **Total long-term debt** | **13209** | **13171** |
| Less: Current portion | 81 | 79 |
| **Long-term debt, net of current portion** | $**13128** | $**13092** |

---

**Senior Unsecured Notes and Senior Secured Notes**

At March 31, 2026, we had senior unsecured notes and senior secured notes with aggregate principal amounts outstanding of $12.662 billion. These notes have fixed interest rates ranging from 4.250% to 6.875% and require semi-annual interest payments in arrears. A payment of the principal and any accrued but unpaid interest is due upon the maturity date of the respective notes, which dates are staggered from November 2027 through November 2033.

**Credit Agreement**

We have a senior secured revolving credit facility (the "Credit Agreement") that provides for revolving loans in an aggregate principal amount of up to $1.900 billion with a $200 million subfacility for standby letters of credit. Our borrowing availability, which is calculated by reference to a borrowing base that is determined by specified percentages of eligible accounts receivable, eligible inventory and Medicaid supplemental payments, was $1.900 billion at March 31, 2026. On that date, we had no cash borrowings and less than $1 million of standby letters of credit outstanding under the Credit Agreement.

**Letter of Credit Facility**

We have a letter of credit facility (as amended to date, the "LC Facility") that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200 million. At March 31, 2026, we had $104 million of standby letters of credit outstanding under the LC Facility.

**NOTE 6. GUARANTEES**

At March 31, 2026, the maximum potential amount of future payments under our revenue guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital-based physician groups providing certain services at our hospitals was $221 million. We had a total liability of $162 million recorded for these guarantees included in other current liabilities in the accompanying Condensed Consolidated Balance Sheet at March 31, 2026.

We have also issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $51 million at March 31, 2026.

**NOTE 7. EMPLOYEE BENEFIT PLANS**

The accompanying Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025 include $25 million and $21 million, respectively, of pre-tax compensation costs related to our stock-based compensation arrangements.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

*Stock Options*

As of March 31, 2026, there were 144,681 stock options outstanding under our share-based compensation plans, which had a weighted average exercise price per share of $24.16. There was no activity related to our stock options during either of the three-month periods ended March 31, 2026 or 2025. All outstanding options were vested and exercisable at March 31, 2026, and the options collectively had an aggregate intrinsic value of $24 million.

*Restricted Stock Units*

The following table presents information about our restricted stock unit ("RSU") activity during the three months ended March 31, 2026:

---

| | | |
|:---|:---|:---|
| | **Number of RSUs** | **Weighted Average**<br>**Grant Date Fair** <br>**Value Per RSU** |
| Unvested at December 31, 2025 | 1440379 | $111.02 |
| &nbsp;&nbsp;&nbsp;Granted | 239518 | $252.66 |
| &nbsp;&nbsp;&nbsp;Performance-based adjustment | 350583 | $110.83 |
| &nbsp;&nbsp;&nbsp;Vested | (851433) | $104.79 |
| &nbsp;&nbsp;&nbsp;Forfeited | (2074) | $151.62 |
| **Unvested at March 31, 2026** | **1176973** | $**171.09** |

---

During the three months ended March 31, 2026, we granted 110,736 RSUs that will vest ratably over a three-year period. In addition, we granted 128,782 performance-based RSUs, the vesting of which is contingent on our achievement of specified performance goals for the years 2026 to 2028. Provided the goals are achieved, the performance-based RSUs that could vest will range from 0% to 250% of the 128,782 units granted, depending on our level of achievement with respect to the performance goals. During the same period, we issued an additional 350,583 RSUs that vested immediately as a result of our level of achievement with respect to previously awarded performance-based RSUs.

During the three months ended March 31, 2025, we granted 284,502 RSUs that will vest ratably over periods ranging from three to four years. In addition, we granted 279,769 performance-based RSUs, the vesting of which is contingent on our achievement of specified performance goals for the years 2025 to 2028. Provided the goals are achieved, the performance-based RSUs that could vest will range from 0% to 250% of the 279,769 units granted, depending on our level of achievement with respect to the performance goals. During the same period, we issued an additional 202,045 RSUs that vested immediately as a result of our level of achievement with respect to previously awarded performance-based RSUs.

The fair value of an RSU is based on our share price on the grant date. The fair value of an RSU with a market-based condition is estimated through the use of a Monte Carlo simulation. Significant inputs used in our valuation of these RSUs included the following:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Expected volatility | 39.0% - 43.8% | 36.6% - 48.0% |
| Risk-free interest rate | 3.4% - 3.5%  | 4.1% - 4.3%  |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**NOTE 8. EQUITY**

The following tables present the changes in consolidated equity (dollars in millions, share amounts in thousands):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Retained Earnings** | **Treasury<br>Stock** | **Noncontrolling<br>Interests** | **Total Equity** |
| | **Shares<br>Outstanding** | **Issued Par<br>Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Retained Earnings** | **Treasury<br>Stock** | **Noncontrolling<br>Interests** | **Total Equity** |
| **Balances at December 31, 2025** | **86952** | $**8** | $**4914** | $**(181)** | $**4415** | $**(4936)** | $**1797** | $**6017** |
| Net income |  |  |  |  | 702 |  | 93 | 795 |
| Distributions paid to noncontrolling interests |  |  |  |  |  |  | (75) | (75) |
| Other comprehensive income |  |  |  | 2 |  |  |  | 2 |
| Purchases (sales) of businesses and noncontrolling interests, net |  |  | 270 |  |  |  | 84 | 354 |
| Repurchases of common stock | (1346) |  |  |  |  | (320) |  | (320) |
| Stock-based compensation expense, tax benefit and issuance of common stock | 518 |  | (60) |  |  |  |  | (60) |
| **Balances at March 31, 2026** | **86124** | $**8** | $**5124** | $**(179)** | $**5117** | $**(5256)** | $**1899** | $**6713** |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Retained Earnings** | **Treasury<br>Stock** | **Noncontrolling<br>Interests** | **Total Equity** |
| | **Shares<br>Outstanding** | **Issued Par<br>Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Loss** | **Retained Earnings** | **Treasury<br>Stock** | **Noncontrolling<br>Interests** | **Total Equity** |
| **Balances at December 31, 2024** | **95109** | $**8** | $**4873** | $**(180)** | $**3008** | $**(3538)** | $**1649** | $**5820** |
| Net income |  |  |  |  | 406 |  | 95 | 501 |
| Distributions paid to noncontrolling interests |  |  |  |  |  |  | (89) | (89) |
| Other comprehensive income |  |  |  | 2 |  |  |  | 2 |
| Purchases (sales) of businesses and noncontrolling interests, net |  |  | (35) |  |  |  | 41 | 6 |
| Repurchases of common stock | (2629) |  |  |  |  | (351) |  | (351) |
| Stock-based compensation expense, tax benefit and issuance of common stock | 405 |  | (12) |  |  |  |  | (12) |
| **Balances at March 31, 2025** | **92885** | $**8** | $**4826** | $**(178)** | $**3414** | $**(3889)** | $**1696** | $**5877** |

---

**Nonredeemable Noncontrolling Interests**

The table below presents our nonredeemable noncontrolling interests balances by segment:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Hospital Operations | $216 | $211 |
| Ambulatory Care | 1683 | 1586 |
| **Total nonredeemable noncontrolling interests** | $**1899** | $**1797** |

---

The table below presents our net income available to nonredeemable noncontrolling interests by segment:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Hospital Operations | $10 | $12 |
| Ambulatory Care | 83 | 83 |
| **Total net income available to nonredeemable noncontrolling interests** | $**93** | $**95** |

---

**Share Repurchase Program Activity**

In July 2024, our board of directors authorized the repurchase of up to $1.500 billion of our common stock through a share repurchase program that has no expiration date. In July 2025, the board authorized a $1.500 billion increase to the program. The share repurchase program does not obligate us to acquire any particular amount of common stock, and it may be suspended for periods or discontinued at any time. Share repurchases may be made in open-market or privately negotiated transactions, at management's discretion subject to market conditions and other factors, in a manner consistent with applicable securities laws and regulations.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

The table below presents repurchase activity under our share repurchase program:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Program** | **Maximum Dollar Value of Shares That May Yet Be Purchased Under the Program** |
| | **(In Thousands)** | | **(In Thousands)** | **(In Millions)** |
| **January 1 through March 31, 2026** | | | | |
| &nbsp;&nbsp;January 1 through January 31, 2026 |  | $— |  | $1490 |
| &nbsp;&nbsp;February 1 through February 28, 2026 |  | $— |  | $1490 |
| &nbsp;&nbsp;March 1 through March 31, 2026 | 1346 | $236.30 | 1346 | $1172 |
| **January 1 through March 31, 2025** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;January 1 through January 31, 2025 |  | $— |  | $1376 |
| &nbsp;&nbsp;&nbsp;February 1 through February 28, 2025 | 1800 | $134.98 | 1800 | $1133 |
| &nbsp;&nbsp;&nbsp;March 1 through March 31, 2025 | 829 | $126.67 | 829 | $1028 |

---

**NOTE 9. NET OPERATING REVENUES**

Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, and managed care and other health plans, as well as certain uninsured patients under our *Compact with Uninsured Patients* and other uninsured discount and charity programs. Net operating revenues for our Hospital Operations segment also include revenues from providing revenue cycle management and value-based care services to hospitals and other healthcare facilities, health systems, physician practices, employers and other clients, as well as income recognized under grant programs.

The table below presents our sources of net operating revenues:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Hospital Operations:** |  |  |
| Net patient service revenues from hospitals and related outpatient facilities: |  |  |
| &nbsp;&nbsp;&nbsp;Medicare | $565 | $548 |
| &nbsp;&nbsp;&nbsp;Medicaid | 356 | 380 |
| &nbsp;&nbsp;&nbsp;Managed care | 2394 | 2400 |
| &nbsp;&nbsp;&nbsp;Uninsured | 9 | 35 |
| &nbsp;&nbsp;&nbsp;Indemnity and other | 150 | 117 |
| &nbsp;&nbsp;&nbsp;Total | 3474 | 3480 |
| Other revenues(1) | 574 | 549 |
| **Total Hospital Operations** | **4048** | **4029** |
| **Ambulatory Care** | **1320** | **1194** |
| **Net operating revenues** | $**5368** | $**5223** |

---

  <br> (1) Primarily revenue from physician practices and revenue cycle management.

During the three months ended March 31, 2026, we recognized $413 million of revenue related to the Omnibus Agreement, which revenue is included in revenue from contract termination in the accompanying Condensed Consolidated Statement of Operations for that period. See Note 1 for additional information regarding this transaction.

The table below presents the composition of net operating revenues for our Ambulatory Care segment:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net patient service revenues | $1266 | $1143 |
| Revenue from other sources | 54 | 51 |
| **Net operating revenues** | $**1320** | $**1194** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**Performance Obligations**

The following table presents revenue from revenue cycle management services that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Nine<br>Months<br> Ending** | **Years Ending** | **Years Ending** | **Years Ending** | **Years Ending** | **Later Years** |
| | | | **December 31,** | **December 31,** | **December 31,** | **December 31,** | **Later Years** |
| |<br>**Total** | **2026** | **2027** | **2028** | **2029** | **2030** | **Later Years** |
| Performance obligations | $2262 | $1823 | $91 | $91 | $91 | $91 | $75 |

---

The amounts in the table primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume- or contingency-based contracts, variable-based escalators, performance incentives, penalties or other variable consideration that is considered constrained. The majority of the fixed-fee revenue for the year ending December 31, 2026 in the table above relates to revenue cycle management services provided to CHI, as further discussed in Note 1.

**NOTE 10. INSURANCE**

**Property Insurance**

We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are issued on an occurrence basis. For both the policy periods of April 1, 2024 through March 31, 2025 and April 1, 2025 through April 30, 2026, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub-limits of $100 million for floods, $200 million for earthquakes in California, $200 million for all other earthquakes and a per-occurrence sub-limit of $200 million per named windstorm with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values for earthquakes in California and named windstorms, and 2% of insured values for earthquakes in the New Madrid fault zone, each with a maximum deductible per claim of $25 million. All other covered losses are subject to a minimum deductible of $5 million per occurrence.

**Professional and General Liability Reserves**

We are self-insured for the majority of our professional and general liability claims, and we purchase insurance from third parties to cover catastrophic claims. At March 31, 2026 and December 31, 2025, the aggregate current and long-term professional and general liability reserves in the accompanying Condensed Consolidated Balance Sheets were $1.241 billion and $1.227 billion, respectively. These accruals include the reserves recorded by our captive insurance subsidiaries and our self-insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. Malpractice expense of $83 million and $87 million was included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025, respectively.

**NOTE 11. CLAIMS AND LAWSUITS**

We operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or "whistleblower" lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, commercial payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment-related claims, private litigation and other legal actions in the ordinary course of business, including potential claims related to, among other things: the care and treatment provided at our hospitals and outpatient facilities; the application of various federal and state labor and privacy laws, rules and regulations; antitrust claims; tax audits; contract disputes (including disagreements with joint venture partners); and other matters. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us; however, we believe that the ultimate resolution of our existing ordinary-course claims and lawsuits will not have a material effect on our business or financial condition.

New claims or inquiries may be initiated against us from time to time. These matters could, among other things: (1) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available; (2) cause

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

us to incur substantial expenses; (3) require significant time and attention from our management; and (4) cause us to close or sell hospitals or outpatient facilities or otherwise modify the way we conduct business.

We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter, but are subject to significant uncertainty regarding numerous factors that could affect the ultimate loss levels. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. We do not disclose an estimate when we have concluded that a loss is either not reasonably possible or a loss, or a range of loss, is not reasonably estimable, based on available information. Given the inherent uncertainties associated with material legal matters, especially those involving governmental agencies, and the indeterminate damages sought in some cases, we are unable to predict the ultimate liability we may incur from such matters, and an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period.

The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Balances at<br>Beginning<br>of Period** | **Litigation and<br>Investigation<br>Costs** | **Cash<br>Payments** | **Other** | **Balances at<br>End of<br>Period** |
| Three months ended March 31, 2026 | $38 | $27 | $(40) | $5 | $30 |
| Three months ended March 31, 2025 | $20 | $17 | $(15) | $— | $22 |

---

**NOTE 12. REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES**

Certain of our investees' partnership and operating agreements contain terms that, upon the occurrence of specified events, could obligate us to purchase some or all of the noncontrolling interests related to our consolidated subsidiaries. The noncontrolling interests subject to these provisions, and the income available to those interests, are not included as part of our equity and are presented as redeemable noncontrolling interests in the accompanying Condensed Consolidated Balance Sheets at March 31, 2026 and December 31, 2025.

The following table presents the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Balances at beginning of period** | $**2956** | $**2727** |
| Net income | 111 | 121 |
| Distributions paid to noncontrolling interests | (122) | (100) |
| Purchases and sales of businesses and noncontrolling interests, net | (808) | 28 |
| **Balances at end of period** | $**2137** | $**2776** |

---

As previously discussed, we redeemed CHI's minority equity interest in Conifer effective January 1, 2026. This redemption resulted in an $846 million decrease in our redeemable noncontrolling interests balance and a $306 million increase in our additional paid-in capital balance. See Note 1 for additional information regarding this transaction.

The following tables present the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Hospital Operations | $58 | $905 |
| Ambulatory Care | 2079 | 2051 |
| **Redeemable noncontrolling interests** | $**2137** | $**2956** |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Hospital Operations | $1 | $27 |
| Ambulatory Care | 110 | 94 |
| **Net income available to redeemable noncontrolling interests** | $**111** | $**121** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**NOTE 13. INCOME TAXES**

A reconciliation between the amount of reported income tax expense and the amount computed by multiplying income before income taxes by the statutory federal tax rate is presented below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| | **Amount** | **Percent** | **Amount** | **Percent** |
| Tax expense at statutory federal rate | $238 | 21.0% | $161 | 21.0% |
| Domestic federal tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Nontaxable or nondeductible items: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax benefit attributable to noncontrolling interests | (43) | (3.8)% | (44) | (5.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 6 | 0.6% | 1 | 0.1% |
| &nbsp;&nbsp;Stock-based compensation tax benefit | (14) | (1.2)% | (4) | (0.5)% |
| &nbsp;&nbsp;State and local income taxes, net of federal income tax effect | 41 | 3.6% | 31 | 4.1% |
| Changes in valuation allowances | (3) | (0.3)% | (2) | (0.3)% |
| Changes in prior year unrecognized tax benefits | 1 | 0.1% |  | —% |
| **Income tax expense** | $**226** | **20.0%** | $**143** | **18.7%** |

---

Income before income taxes for the three months ended March 31, 2026 and 2025 was $1.132 billion and $765 million, respectively. Our provision for income taxes during interim reporting periods is calculated by applying an estimate of the annual effective tax rate to "ordinary" income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. In calculating "ordinary" income, non-taxable income available to noncontrolling interests was deducted from pre-tax income. During the three months ended March 31, 2026, we recorded an income tax benefit of $3 million to decrease the valuation allowance, including an increase of $1 million related to interest expense carryforwards and a $4 million decrease related to a change in the realizability of deferred tax assets. During the three months ended March 31, 2025, we recorded an income tax benefit of $1 million to decrease the valuation allowance, including an increase of $3 million related to interest expense carryforwards and a decrease of $4 million related to a change in the realizability of deferred tax assets.

There were no adjustments to our estimated liabilities for uncertain tax positions during the three months ended March 31, 2026. The total amount of unrecognized tax benefits as of March 31, 2026 was $69 million, all of which, if recognized, would affect our effective tax rate and income tax benefit.

Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our condensed consolidated statements of operations. Approximately $1 million of interest and penalties related to accrued liabilities for uncertain tax positions are included in the accompanying Condensed Consolidated Statement of Operations for the three months ended March 31, 2026. Total accrued interest and penalties on unrecognized tax benefits at March 31, 2026 were $11 million.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**NOTE 14. EARNINGS PER COMMON SHARE**

The following table reconciles the numerators and denominators of our basic and diluted earnings per common share calculations. Net income available to our common shareholders is expressed in millions and weighted average shares are expressed in thousands.

---

| | | | |
|:---|:---|:---|:---|
| | **Net Income Available** <br>**to Common**<br>**Shareholders**<br>**(Numerator)** | **Weighted Average Shares**<br>**(Denominator)** | **Per-Share Amount** |
| **Three Months Ended March 31, 2026** | | | |
| Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share | $702 | 86801 | $8.09 |
| Effect of dilutive instruments |  | 795 | (0.08) |
| **Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share** | $**702** | **87596** | $**8.01** |
| **Three Months Ended March 31, 2025** |  |  |  |
| Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share | $406 | 94242 | $4.31 |
| Effect of dilutive instruments |  | 777 | (0.04) |
| **Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share** | $**406** | **95019** | $**4.27** |

---

Dilutive instruments during the three months ended March 31, 2026 and 2025 consisted of stock options, RSUs, convertible long-term incentive awards, deferred compensation units and dividends on subsidiary preferred stock.

**NOTE 15. FAIR VALUE MEASUREMENTS** 

We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non-financial assets and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows.

**Non-Recurring Fair Value Measurements**

Our non-financial assets and liabilities not permitted or required to be measured at fair value on a recurring basis typically relate to long-lived assets held and used, long-lived assets held for sale and goodwill. The following table presents information about assets measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values at December 31, 2025. There were no significant non-recurring fair value measurements at March 31, 2026.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total** | **Quoted Prices<br>in Active<br>Markets for<br>Identical Assets<br>(Level 1)** | **Significant Other<br>Observable Inputs<br>(Level 2)** | **Significant<br>Unobservable<br>Inputs<br>(Level 3)** |
| **December 31, 2025** | | | | |
| &nbsp;&nbsp;&nbsp;Long-lived assets held for sale | $**62** | $— | $62 | $— |

---

**Financial Instruments**

The fair value of our long-term debt (except for any borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs. At March 31, 2026 and December 31, 2025, the estimated fair value of our long-term debt was approximately 99.6% and 100.9%, respectively, of the carrying value of the debt. The inputs used to estimate the fair value of the CHI Note Receivable are considered to be Level 3 inputs. At March 31, 2026, the estimated fair value of the CHI Note Receivable was approximately 100.0% of its carrying value.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**NOTE 16. ACQUISITIONS**

During the three months ended March 31, 2026, we used $121 million of cash for acquisition-related activity, of which $120 million related to acquisitions completed during that period and $1 million related to measurement-period adjustments for acquisitions completed during 2025. During the three months ended March 31, 2025, we used $27 million of cash for acquisition-related activity, of which $17 million related to acquisitions and consolidations completed during that period and $10 million related to measurement-period adjustments for acquisitions completed during 2024.

We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase prices allocated over those fair values is recorded as goodwill. The purchase price allocations for certain acquisitions completed in 2026 and 2025 are preliminary. We are in the process of assessing working capital balances and lease and other agreements assumed, as well as obtaining and evaluating valuations of the acquired property and equipment, management contracts and other intangible assets, and noncontrolling interests. Therefore, those purchase price allocations, including goodwill, recorded in the accompanying Condensed Consolidated Financial Statements are subject to adjustment once the assessments and valuation work are completed and evaluated. Such adjustments will be recorded as soon as practical and within the measurement period as defined by the accounting literature. During the three months ended March 31, 2026, we adjusted the preliminary purchase price allocations of certain Ambulatory Care segment acquisitions completed in 2025 based on the results of completed valuations and post-closing working capital adjustments. These adjustments resulted in a decrease of $2 million in goodwill recognized.

The table below presents the preliminary or final purchase price allocations for acquisitions made during the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Current assets | $19 | $9 |
| Property and equipment | 10 | 7 |
| Other intangible assets | 2 |  |
| Goodwill | 191 | 95 |
| Long-term operating lease assets | 12 | 11 |
| Other long-term assets | 2 | 6 |
| Previously held investments in unconsolidated affiliates |  | (9) |
| Current liabilities | (4) | (8) |
| Current portion of long-term lease liabilities | (1) |  |
| Long-term operating lease liabilities | (11) | (11) |
| Other long-term liabilities | (9) | (11) |
| Redeemable noncontrolling interests in equity of consolidated subsidiaries | (47) | (36) |
| Noncontrolling interests | (44) | (27) |
| Cash paid, net of cash acquired | (120) | (17) |
| **Gains on consolidations** | $**—** | $**9** |

---

The goodwill generated from our 2026 acquisitions, the majority of which we believe will be deductible for income tax purposes, can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. Goodwill recognized related to our acquisition activity during the three months ended March 31, 2026 was entirely attributable to our Ambulatory Care segment.

**NOTE 17. SEGMENT INFORMATION**

The following tables present amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, as applicable.

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| **Assets:** | | |
| &nbsp;&nbsp;&nbsp;Hospital Operations | $17930 | $16586 |
| &nbsp;&nbsp;&nbsp;Ambulatory Care | 13273 | 13091 |
| &nbsp;&nbsp;&nbsp;**Total** | $**31203** | $**29677** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Capital expenditures:** |  |  |
| &nbsp;&nbsp;&nbsp;Hospital Operations | $148 | $148 |
| &nbsp;&nbsp;&nbsp;Ambulatory Care | 32 | 25 |
| &nbsp;&nbsp;&nbsp;**Total** | $**180** | $**173** |
| **Depreciation and amortization:** |  |  |
| &nbsp;&nbsp;&nbsp;Hospital Operations | $188 | $167 |
| &nbsp;&nbsp;&nbsp;Ambulatory Care | 41 | 39 |
| &nbsp;&nbsp;&nbsp;**Total** | $**229** | $**206** |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| | **Hospital Operations** | **Ambulatory Care** | **Total** |
| Net operating revenues | $4048 | $1320 | $5368 |
| Equity in earnings of unconsolidated affiliates |  | 51 | 51 |
| Less: |  |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 1844 | 330 | 2174 |
| &nbsp;&nbsp;&nbsp;Supplies | 604 | 357 | 961 |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 922 | 200 | 1122 |
| &nbsp;&nbsp;&nbsp;**Adjusted EBITDA** | $**678** | $**484** | **1162** |
| **Reconciliation of Adjusted EBITDA:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Revenue from contract termination |  |  | 413 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization |  |  | (229) |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs |  |  | (24) |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs |  |  | (27) |
| &nbsp;&nbsp;&nbsp;Interest expense |  |  | (205) |
| &nbsp;&nbsp;&nbsp;Other non-operating income, net |  |  | 41 |
| &nbsp;&nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities |  |  | 1 |
| &nbsp;&nbsp;&nbsp;**Income before income taxes** |  |  | $**1132** |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **Hospital Operations** | **Ambulatory Care** | **Total** |
| Net operating revenues | $4029 | $1194 | $5223 |
| Equity in earnings of unconsolidated affiliates | 2 | 54 | 56 |
| Less: |  |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 1824 | 295 | 2119 |
| &nbsp;&nbsp;&nbsp;Supplies | 589 | 318 | 907 |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 911 | 179 | 1090 |
| &nbsp;&nbsp;&nbsp;**Adjusted EBITDA** | $**707** | $**456** | **1163** |
| **Reconciliation of Adjusted EBITDA:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization |  |  | (206) |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs |  |  | (19) |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs |  |  | (17) |
| &nbsp;&nbsp;&nbsp;Interest expense |  |  | (204) |
| &nbsp;&nbsp;&nbsp;Other non-operating income, net |  |  | 26 |
| &nbsp;&nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities |  |  | 22 |
| &nbsp;&nbsp;&nbsp;**Income before income taxes** |  |  | $**765** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**INTRODUCTION TO MANAGEMENT'S DISCUSSION AND ANALYSIS**

The purpose of this section, Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to give context to the analysis of our financial information, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Management Overview

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Forward-Looking Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sources of Revenue for Our Hospital Operations and Services Segment

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Results of Operations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Liquidity and Capital Resources

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Critical Accounting Estimates

Our business consists of our Hospital Operations and Services ("Hospital Operations") segment and our Ambulatory Care segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, a network of employed physicians and ancillary outpatient facilities. At March 31, 2026, our subsidiaries operated 50 hospitals serving primarily urban and suburban communities in eight states. Our Hospital Operations segment also included 132 outpatient facilities, namely urgent care centers, imaging centers, off-campus hospital emergency departments and micro-hospitals, at March 31, 2026. In addition, our Hospital Operations segment provides revenue cycle management and value-based care services to hospitals and other healthcare facilities, health systems, physician practices, employers and other clients through Conifer Health Solutions, LLC ("Conifer").

Our Ambulatory Care segment, through USPI Holding Company, Inc. (together with its subsidiaries, "USPI"), held ownership interests in 541 ambulatory surgery centers (each, an "ASC"), 407 of which are consolidated, and 26 surgical hospitals, eight of which are consolidated, in 37 states at March 31, 2026. USPI's facilities offer a range of procedures and service lines, including, among other specialties: orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology (ear, nose and throat); ophthalmology; and urology.

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per adjusted admission and per adjusted patient day amounts). Continuing operations information includes the results of all facilities operated during any portion of the periods presented, and it reflects the performance of those facilities only for the time periods in which we operated them. Continuing operations information excludes the results of our hospitals and other businesses classified as discontinued operations for accounting purposes. We believe this presentation is useful to investors because continuing operations information reflects the impact of the addition or disposition of individual hospitals and other operations on our volumes, revenues and expenses.

In certain cases, information presented in MD&A for our Hospital Operations segment is described as presented on a same-hospital basis, which includes facilities we operated for the entirety of the periods presented. For the three-month periods ended March 31, 2026 and 2025, information presented on a same-hospital basis includes the results of our same 49 hospitals and those outpatient centers we operated throughout both periods, and excludes the results of: Florida Coast Medical Center, the acute care hospital we opened in Florida in September 2025; businesses classified as discontinued operations for accounting purposes during those periods; and other ancillary facilities acquired or divested during the reporting periods that have a limited financial or operational impact. We present same-hospital data because we believe it provides investors with useful information regarding the performance of our current portfolio of hospitals and other operations that are comparable for the periods presented. Furthermore, same-hospital data may more clearly reflect recent trends we are experiencing with respect to volumes, revenues and expenses exclusive of variations caused by the addition or disposition of individual hospitals and other operations.

Our Ambulatory Care segment reports growth data on a same-facility systemwide basis, which includes both consolidated and unconsolidated facilities held at the end of the period, as well as facilities acquired during the period on a pro forma basis as if owned for the full period. Divested facilities are generally excluded; however, management may include facilities sold near the end of the period when, in its judgment, their inclusion provides financial statement users with a better understanding of the segment's performance. This approach offers insights into the performance of our current portfolio by

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

excluding variations from facility acquisitions or dispositions. Although we do not record the revenues of unconsolidated facilities, this information is important for understanding the financial performance of our Ambulatory Care segment, as these revenues form the basis for calculating management services revenues and equity in earnings of unconsolidated affiliates. Additionally, this presentation enhances comparability across periods.

We present certain operational metrics and statistics in order to provide additional insight into our operational performance efficiency and to help investors better understand management's view and strategic focus. We define these operational metrics and statistics as follows:

*Adjusted admissions—*represents actual admissions in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues;

*Adjusted patient days—*represents actual patient days in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient days by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues; and

*Utilization of licensed bed*s*—*represents patient days divided by the number of days in the period divided by average licensed beds.

We also present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable, and we present certain metrics on a per adjusted admission and per adjusted patient day basis to show trends other than volume.

**MANAGEMENT OVERVIEW**

***OPERATING ENVIRONMENT AND TRENDS***

In the Management Overview section of MD&A in our Annual Report on Form 10-K for the year ended December 31, 2025 ("Annual Report"), we describe several key trends that continue to impact the healthcare industry, along with other factors affecting our business environment and operations, including the potential impact of changes in federal and state healthcare laws, regulations, funding policies and reimbursement practices, as well as the influence of geopolitical dynamics, trade tensions, tariffs and export control rules on pricing and availability within global supply chains. These challenges underscore the importance of operational discipline and adaptive cost management as we navigate the evolving healthcare landscape.

***STRATEGIES***

*Expanding Our Ambulatory Care Segment—*We continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth in our physician relationships and service lines, construction of new outpatient centers and strategic partnerships. We believe USPI's ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in surgical techniques, medical technology and anesthesia, as well as the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase over time. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

*Driving Growth in Our Hospital Operations Segment—*We remain committed to better positioning our hospitals and competing more effectively in the ever-evolving healthcare environment by focusing on driving performance through operational effectiveness, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher-demand clinical service lines, expanding patient and physician access, and optimizing our portfolio of assets. We believe our efforts in these areas improve the quality of care we deliver and enhance growth.

*Improving the Customer Care Experience—*As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: (1) establishing networks of physicians and facilities that provide convenient access to services across the care continuum; (2) expanding service lines aligned with growing community demand, including a focus on aging and chronic disease patients; (3) offering greater affordability and predictability, including simplified registration and discharge procedures, particularly in our outpatient centers; (4) improving our culture of service; and (5) offering health programs and educational materials tailored to meet the needs of the communities we serve.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

Recent advancements in technology and applications in healthcare have allowed us to accelerate the adoption of artificial intelligence ("AI") and Generative AI-enabled tools in areas such as clinical care coordination, medical documentation, revenue cycle management and administrative services. When used responsibly, we believe AI has the potential to enhance our business processes and support efficient delivery of high-quality care.

*Improving Profitability—*We continue to focus on growing patient volumes and effective cost management as a means to improve profitability. We believe that emphasis on higher-demand clinical service lines, focus on expanding our ambulatory care business, cultivation of our culture of service and utilizing contracting strategies that create shared value with payers should help us grow our patient volumes over time. We are also continuing to pursue new opportunities to enhance efficiency, including further integration of enterprise-wide centralized support functions, outsourcing additional functions unrelated to direct patient care and reducing clinical contract variation.

*Managing Our Capital Structure*—All of our long-term debt has a fixed rate of interest, except for outstanding borrowings under our senior secured revolving credit facility (the "Credit Agreement"), of which we had none at March 31, 2026. In addition, the maturity dates of our notes are staggered from 2027 through 2033. We believe that our capital structure helps to minimize the near-term impact of increases in interest rates, and the staggered maturities of our debt allow us to retire or refinance our debt over time.

In the three months ended March 31, 2026, we repurchased 1.346 million shares of our common stock pursuant to our share repurchase program. This program has no expiration date, it does not obligate us to acquire any particular amount of common stock, and it may be suspended for periods or discontinued at any time. At March 31, 2026, there was $1.172 billion available under the program for future repurchases.

Our ability to execute on our strategies and respond to the aforementioned trends in the current operating environment is subject to numerous risks and uncertainties, all of which may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

***RECENT RESULTS OF OPERATIONS***

The following table presents selected operating statistics for our Hospital Operations and Ambulatory Care segments on a continuing operations basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** | **Increase<br>(Decrease)** |
| | **2026** | **2025** | **Increase<br>(Decrease)** | **Increase<br>(Decrease)** |
| **Hospital Operations – hospitals and related outpatient facilities:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Number of hospitals (at end of period) | 50 | 49 | 1 | (1) |
| &nbsp;&nbsp;&nbsp;Total admissions | 120899 | 120090 | 0.7% |  |
| &nbsp;&nbsp;&nbsp;Adjusted admissions | 215353 | 213039 | 1.1% |  |
| &nbsp;&nbsp;&nbsp;Paying admissions (excludes charity and uninsured) | 115610 | 115285 | 0.3% |  |
| &nbsp;&nbsp;&nbsp;Charity and uninsured admissions | 5289 | 4805 | 10.1% |  |
| &nbsp;&nbsp;&nbsp;Admissions through emergency department | 92179 | 91387 | 0.9% |  |
| &nbsp;&nbsp;&nbsp;Emergency department visits, outpatient | 458352 | 474619 | (3.4)% |  |
| &nbsp;&nbsp;&nbsp;Total emergency department visits | 550531 | 566006 | (2.7)% |  |
| &nbsp;&nbsp;&nbsp;Total surgeries | 66019 | 66255 | (0.4)% |  |
| &nbsp;&nbsp;&nbsp;Patient days — total | 599452 | 605786 | (1.0)% |  |
| &nbsp;&nbsp;&nbsp;Adjusted patient days | 1024706 | 1036716 | (1.2)% |  |
| &nbsp;&nbsp;&nbsp;Average length of stay (days) | 4.96 | 5.04 | (1.6)% |  |
| &nbsp;&nbsp;&nbsp;Average licensed beds | 12499 | 12435 | 0.5% |  |
| &nbsp;&nbsp;&nbsp;Utilization of licensed beds | 53.3% | 54.1% | (0.8)% | (1) |
| &nbsp;&nbsp;&nbsp;Total visits | 1351868 | 1405921 | (3.8)% |  |
| &nbsp;&nbsp;&nbsp;Paying visits (excludes charity and uninsured) | 1250348 | 1310928 | (4.6)% |  |
| &nbsp;&nbsp;&nbsp;Charity and uninsured visits | 101520 | 94993 | 6.9% |  |
| **Ambulatory Care:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Total consolidated facilities (at end of period) | 415 | 387 | 28 | (1) |
| &nbsp;&nbsp;&nbsp;Total consolidated cases | 478211 | 454288 | 5.3% |  |

---

(1) The change is the difference between the 2026 and 2025 amounts or percentages presented.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

Total admissions increased by 809, or 0.7%, total emergency department visits decreased by 15,475, or 2.7%, and total surgeries decreased by 236, or 0.4%, in the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

The 5.3% increase in our Ambulatory Care segment's total consolidated cases in the three months ended March 31, 2026, as compared to the same period in 2025, was primarily attributable to incremental case volume from newly acquired and developed ASCs and same-facility case volume growth, net of the impact of the closure and sale of certain facilities.

The following table presents net operating revenues by segment on a continuing operations basis:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** |
| **Revenues** | **2026** | **2025** | **Increase<br>(Decrease)** |
| Hospital Operations | $4048 | $4029 | 0.5% |
| Ambulatory Care | 1320 | 1194 | 10.6% |
| **Total** | $**5368** | $**5223** | **2.8%** |

---

Consolidated net operating revenues increased by $145 million, or 2.8%, in the three months ended March 31, 2026 compared to the same period in 2025. The increase of $19 million, or 0.5%, in our Hospital Operations segment's net operating revenues for the three-month period in 2026, as compared to the same period in 2025, was primarily attributable to higher patient volumes, partially offset by a less favorable payer mix during the 2026 period.

Net operating revenues in our Ambulatory Care segment increased by $126 million, or 10.6%, in the three months ended March 31, 2026 compared to the same period in 2025. This change was primarily driven by our 2025 and 2026 acquisitions, de novo development and purchases of controlling interests, partially offset by the impact of the closure and sale of certain facilities. Higher net revenue per case during the 2026 period, driven by incremental revenue from negotiated commercial rate increases, higher patient acuity and the addition of new service lines, also contributed to this increase.

The following table presents information about selected operating expenses by segment on a continuing operations basis:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** |
| | **2026** | **2025** | **Increase<br>(Decrease)** |
| **Hospital Operations:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | $1844 | $1824 | 1.1% |
| &nbsp;&nbsp;&nbsp;Supplies | 604 | 589 | 2.5% |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 922 | 911 | 1.2% |
| &nbsp;&nbsp;&nbsp;**Total** | $**3370** | $**3324** | **1.4%** |
| **Ambulatory Care:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | $330 | $295 | 11.9% |
| &nbsp;&nbsp;&nbsp;Supplies | 357 | 318 | 12.3% |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 200 | 179 | 11.7% |
| &nbsp;&nbsp;&nbsp;**Total** | $**887** | $**792** | **12.0%** |
| **Total:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | $2174 | $2119 | 2.6% |
| &nbsp;&nbsp;&nbsp;Supplies | 961 | 907 | 6.0% |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 1122 | 1090 | 2.9% |
| &nbsp;&nbsp;&nbsp;**Total** | $**4257** | $**4116** | **3.4%** |
| **Rent/lease expense(1):** |  |  |  |
| &nbsp;&nbsp;&nbsp;Hospital Operations | $54 | $53 | 1.9% |
| &nbsp;&nbsp;&nbsp;Ambulatory Care | 48 | 43 | 11.6% |
| &nbsp;&nbsp;&nbsp;**Total** | $**102** | $**96** | **6.3%** |

---

 <br> <u>(1)</u> <u> Included in other operating expenses, net.</u>

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

The following table presents information about our Hospital Operations segment's selected operating expenses per adjusted admission on a continuing operations basis:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** |
| | **2026** | **2025** | **Increase<br>(Decrease)** |
| Salaries, wages and benefits per adjusted admission | $8565 | $8564 | —% |
| Supplies per adjusted admission | 2808 | 2763 | 1.6% |
| Other operating expenses, net per adjusted admission | 4280 | 4278 | —% |
| **Total per adjusted admission** | $**15653** | $**15605** | **0.3%** |

---

Salaries, wages and benefits expense for our Hospital Operations segment increased by $20 million, or 1.1%, in the three months ended March 31, 2026 compared to the same period in 2025. This increase was primarily attributable to annual merit increases for certain of our employees and higher employee benefits costs, partially offset by lower incentive compensation expense, contract labor costs and premium pay as compared to the 2025 period. On a per adjusted admission basis, salaries, wages and benefits expense in our Hospital Operations segment during the three months ended March 31, 2026 was consistent with the three months ended March 31, 2025.

Supplies expense for our Hospital Operations segment increased by $15 million, or 2.5%, during the three months ended March 31, 2026 compared to the three months ended March 31, 2025. This change was primarily due to higher patient volumes during the 2026 period, partially offset by our continued focus on cost-efficiency measures. These measures include product standardization, contract management, improved utilization, bulk purchases, focused spending and operational improvements, among others. On a per adjusted admission basis, supplies expense increased by 1.6% in the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

Other operating expenses for our Hospital Operations segment increased by $11 million, or 1.2%, in the three months ended March 31, 2026 compared to the same period in 2025. This increase was primarily attributable to an increase in medical fees, as well as higher professional and consulting costs, partially offset by a decrease in malpractice expense during the 2026 period. On a per adjusted admission basis, other operating expenses during the three months ended March 31, 2026 were consistent with the three months ended March 31, 2025.

***LIQUIDITY AND CAPITAL RESOURCES OVERVIEW***

Cash and cash equivalents were $2.967 billion at March 31, 2026 compared to $2.883 billion at December 31, 2025. Significant cash flow items in the three months ended March 31, 2026 included:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net cash provided by operating activities before payments for interest, taxes, restructuring charges, acquisition-related costs, and litigation costs and settlements of $1.730 billion;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $180 million of capital expenditures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Purchases of businesses or joint venture interests, net of cash acquired, of $121 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $318 million of payments to purchase approximately 1.346 million shares of our common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Distributions paid to noncontrolling interests totaling $197 million; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• $549 million in purchases of noncontrolling interests.

Net cash provided by operating activities was $1.641 billion in the three months ended March 31, 2026 compared to $815 million in the three months ended March 31, 2025. Key factors contributing to the change between the 2026 and 2025 periods included the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contract termination payments received of $540 million in the 2026 period;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Interest payments that were $75 million lower in the 2026 period; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The timing of working capital items.

**FORWARD-LOOKING STATEMENTS**

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-looking statements, including (but not limited to) disclosures regarding (1) our future

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

earnings, financial position, and operational and strategic initiatives, (2) developments in the healthcare industry, and (3) the anticipated impacts of economic and public health conditions and government actions on our business. Forward-looking statements represent management's expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are indeterminate. They involve known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, but are not limited to, the risks described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.

Readers should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report and not place undue reliance on forward-looking statements. Should one or more of the risks and uncertainties described in these reports occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statement. We specifically disclaim any obligation to revise or update any information contained in a forward-looking statement or any forward-looking statement in its entirety except as required by law.

All forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary information.

**SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS SEGMENT**

We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity-based health insurance companies and uninsured patients (that is, patients who do not have health insurance and are not covered by some other form of third-party arrangement).

The following table presents the sources of net patient service revenues for our hospitals and related outpatient facilities, expressed as percentages of net patient service revenues from all sources on a continuing operations basis:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)(1)** |
| | **2026** | **2025** | **Increase<br>(Decrease)(1)** |
| Medicare | 16.3% | 15.7% | 0.6% |
| Medicaid | 10.2% | 10.9% | (0.7)% |
| Managed care(2) | 68.9% | 69.0% | (0.1)% |
| Uninsured | 0.3% | 1.0% | (0.7)% |
| Indemnity and other | 4.3% | 3.4% | 0.9% |

---

(1) The change is the difference between the 2026 and 2025 percentages presented.

(2) Includes Medicare and Medicaid managed care programs.

Our payer mix on an admissions basis for our hospitals, expressed as a percentage of total admissions from all sources on a continuing operations basis, is presented below:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)(1)** |
| **Admissions from:** | **2026** | **2025** | **Increase<br>(Decrease)(1)** |
| Medicare | 19.4% | 19.5% | (0.1)% |
| Medicaid | 3.7% | 3.7% | —% |
| Managed care(2) | 68.5% | 69.2% | (0.7)% |
| Charity and uninsured | 4.4% | 4.0% | 0.4% |
| Indemnity and other | 4.0% | 3.6% | 0.4% |

---

(1) The change is the difference between the 2026 and 2025 percentages presented.

(2) Includes Medicare and Medicaid managed care programs.

***GOVERNMENT PROGRAMS***

The Centers for Medicare & Medicaid Services ("CMS") is an agency of the U.S. Department of Health and Human Services that administers a number of government programs authorized by federal law; it is the single largest payer of healthcare services in the United States. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, as well as some younger people with certain disabilities and conditions, and is provided without regard to income or assets. Medicaid is co-administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation's main public health insurance program for people with low incomes and is the largest

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

source of health coverage in the United States. The Children's Health Insurance Program ("CHIP"), which is also co-administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. Funding for the CHIP has been reauthorized through federal fiscal year ("FFY") 2029.

**Recent and Potential Future Changes to Healthcare Policy**

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the "Affordable Care Act"), extended health coverage to millions of uninsured legal U.S. residents through a combination of private sector health insurance reforms and public program expansion. The expansion of Medicaid in 40 states (including four of the eight states in which we operate acute care and specialty hospitals) and the District of Columbia is currently financed through:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• negative "productivity adjustments" to the annual market basket updates, which began in 2011 and do not expire under current law; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reductions to Medicare and Medicaid disproportionate share hospital ("DSH") payments, which began for Medicare payments in FFY 2014 and, under current law, are scheduled to commence for Medicaid payments on October 1, 2027.

The expansion of health insurance coverage under the Affordable Care Act resulted in an increase in the number of patients using our facilities with either private or public program coverage and a decrease in uninsured and charity care admissions. Although a substantial portion of our patient volumes and, as a result, our revenues have historically been derived from government healthcare programs, reductions to our reimbursement under the Medicare and Medicaid programs due to the Affordable Care Act have been partially offset by increased revenues from providing care to previously uninsured individuals.

Over the past several years, various laws and regulations lengthened the enrollment period, expanded income eligibility, and provided enhanced premium tax credits to eligible individuals purchasing Affordable Care Act coverage through state and federal health insurance marketplaces – all of which led to higher enrollment numbers, particularly in states that have not expanded Medicaid. Certain of these provisions expired at the end of 2025, resulting in significant increases in health insurance premiums and decreases in enrollment and insurance coverage. These changes have contributed to a rise in the number of uninsured and shifts of individuals from commercial coverage to government program coverage or other more limited coverage alternatives. As a result, we expect an adverse impact on our patient volumes, payer mix and revenues. We continue to monitor the extent to which decreases in insurance coverage will adversely affect these metrics and our overall results of operations.

The impact of The One Big Beautiful Bill Act ("OBBBA"), which was enacted in July 2025, is expected to be far-reaching, with significant implications for states, their healthcare programs and consumers. Key provisions, the most consequential of which are set to take effect beginning in 2027, include new Medicaid work requirements, caps on state-directed payments, limits on provider taxes, stricter eligibility checks, financial incentives for accurate state administration and reforms to federal subsidies.

Once the OBBBA is implemented, the Congressional Budget Office anticipates that millions of individuals will lose health insurance by 2034. With respect to Medicaid, these coverage losses may primarily be attributable to policy changes, including the work requirements, more frequent eligibility reviews and limits on eligibility. With respect to individuals who purchase Affordable Care Act coverage through state and federal marketplaces, these losses may primarily be attributable to changes in pre-verification requirements and limits to tax credit eligibility. States are awaiting additional guidance from federal agencies on several provisions and are likely to have variation in the details of how they will implement the provisions of the law.

Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state's budget, states can be expected to reevaluate their financial plans for 2026 and beyond. The OBBBA's legislative and forthcoming regulatory changes may result in material reductions to Medicaid payments, changes and reductions to Medicaid supplemental payment programs, and payment delays. Federal government denials or delayed approvals of state waiver applications or extension requests could also materially impact Medicaid funding levels, most significantly in those states that have expanded Medicaid.

At this time, we cannot estimate the OBBBA's impact, nor can we predict the timing of that impact, on our future business, financial condition or results of operations, however, we may experience decreased payments (including supplemental

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

payments) from Medicare, Medicaid and other government programs, as well as delays in the timing of payments to our facilities.

We also cannot predict whether or how Congress may further modify provisions of or relating to the Affordable Care Act, the OBBBA or other laws affecting the healthcare industry generally, nor can we predict how government agencies or the current administration might further influence, promulgate or implement rules, regulations or executive orders that affect the healthcare industry directly or indirectly.

To the extent the rates paid by governmental payers are materially reduced, the scope of services covered by governmental payers is significantly limited, eligibility or enrollment is further restricted, there are changes to align payment rates for certain procedures across various care settings in a site neutral manner, or we or one or more of our hospitals are excluded from participation in the Medicare or Medicaid program or any other government healthcare program, there may be a material adverse effect on our business, financial condition, results of operations or cash flows. Future federal and state healthcare funding policy changes, along with other initiatives and requirements, may, among other things, adversely affect our patient volumes, case mix and revenue mix, increase our operating costs, materially reduce the reimbursement we receive for our services, diminish our competitive position or require us to expend resources to modify certain aspects of our operations.

**Medicare**

Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes "Part A" and "Part B"), is a fee-for-service ("FFS") payment system. The other option, called Medicare Advantage (sometimes called "Part C" or "MA Plans"), includes health maintenance organizations ("HMOs"), preferred provider organizations ("PPOs"), private FFS Medicare special needs plans and Medicare medical savings account plans. Our total net patient service revenues from operation of the hospitals and related outpatient facilities in our Hospital Operations segment for services provided to patients enrolled in the Original Medicare Plan were $565 million and $548 million for the three months ended March 31, 2026 and 2025, respectively. A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under "Regulatory and Legislative Updates" below.

**Medicaid**

Medicaid programs and the corresponding reimbursement methodologies vary from state-to-state and from year-to-year. In addition to traditional Medicaid programs, we also receive DSH and other supplemental revenues under various state Medicaid programs. All Medicaid patient service revenue is presented net of provider taxes or assessments paid by our hospitals. During the three months ended March 31, 2026 and 2025, revenue from Medicaid programs included $304 million and $326 million, respectively, of revenue attributable to DSH and other supplemental programs. Revenues from Medicaid programs constituted approximately 10% and 11% of the total net patient service revenues of our hospitals and related outpatient facilities for the three-month periods ended March 31, 2026 and 2025, respectively.

Because we cannot predict what actions the federal government or the states may take under existing or future legislation and/or regulatory changes to address budget gaps, deficits, Medicaid expansion, Medicaid eligibility redeterminations, provider fee programs, state-directed payment programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation or regulatory action might have on our business; however, the impact on our future financial position, results of operations or cash flows could be material.

**Regulatory and Legislative Updates**

Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems, as well as other government programs impacting our business, are provided below.

*Proposed Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems*—Section 1886(d) of the Social Security Act requires CMS to update Medicare inpatient FFS payment rates for hospitals reimbursed under the inpatient prospective payment systems ("IPPS") annually. The updates generally become effective October 1, the beginning of the FFY. In April 2026, CMS issued proposed changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2027 Rates ("Proposed IPPS Rule"). According to CMS, the combined impact of the proposed payment and policy changes in the Proposed IPPS Rule for operating costs will yield an average 1.0% increase in Medicare operating payments for proprietary hospitals in FFY 2027.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

***MANAGED CARE***

As described in detail in our Annual Report, in addition to payments from government programs, we receive revenue under contracts with commercial insurers, including both managed care arrangements with various HMOs and PPOs and indemnity-based agreements. These contracts offer varying structures for patient access, utilization and reimbursement. Our top 10 managed care payers generated 67% of our managed care net patient service revenues for the three months ended March 31, 2026. During the same period, national payers generated 47% of our managed care net patient service revenues; the remainder came from regional or local payers.

The amount of our managed care net patient service revenues, including Medicare and Medicaid managed care programs, from our hospitals and related outpatient facilities during the three months ended March 31, 2026 and 2025 was $2.394 billion and $2.400 billion, respectively. All Medicaid managed care patient service revenue is presented net of provider taxes or assessments paid by our hospitals.

***UNINSURED PATIENTS***

Uninsured patients are patients who do not qualify for government programs payments, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. We provide financial assistance through our *Compact with Uninsured Patients*, which is designed to offer discounts to certain uninsured patients, and our charity and uninsured discount programs for uninsured patients who are unable to pay for the healthcare services they receive. The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Estimated costs for: |  |  |
| &nbsp;&nbsp;&nbsp;Uninsured patients | $108 | $114 |
| &nbsp;&nbsp;&nbsp;Charity care patients | 34 | 17 |
| &nbsp;&nbsp;&nbsp;**Total** | $**142** | $**131** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**RESULTS OF OPERATIONS**

The following table presents our consolidated net operating revenues, operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, on a continuing operations basis:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Net operating revenues:** |  |  |
| &nbsp;&nbsp;&nbsp;Hospital Operations | $4048 | $4029 |
| &nbsp;&nbsp;&nbsp;Ambulatory Care | 1320 | 1194 |
| **Net operating revenues** | **5368** | **5223** |
| **Revenue from contract termination** | **413** | **—** |
| **Equity in earnings of unconsolidated affiliates** | **51** | **56** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 2174 | 2119 |
| &nbsp;&nbsp;&nbsp;Supplies | 961 | 907 |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 1122 | 1090 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 229 | 206 |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 24 | 19 |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 27 | 17 |
| &nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities | (1) | (22) |
| **Operating income** | $**1296** | $**943** |
| **Net operating revenues** | **100.0%** | **100.0%** |
| **Revenue from contract termination** | **7.7%** | **— %** |
| **Equity in earnings of unconsolidated affiliates** | **1.0%** | **1.1%** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 40.5% | 40.6% |
| &nbsp;&nbsp;&nbsp;Supplies | 17.9% | 17.4% |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 20.9% | 20.9% |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 4.3% | 3.9% |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 0.5% | 0.3% |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 0.5% | 0.3% |
| &nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities | —% | (0.4)% |
| **Operating income** | **24.1%** | **18.1%** |

---

During the three months ended March 31, 2026, we recognized $413 million of revenue related to the termination of the revenue cycle management agreement between Catholic Health Initiatives, now known as CommonSpirit Health, and Conifer. See Note 1 to the accompanying Condensed Consolidated Financial Statements for additional information regarding this transaction.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

The following tables present our net operating revenues, operating expenses and operating income, both in dollar amounts and as percentages of net operating revenues, by segment on a continuing operations basis:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| | **Hospital Operations** | **Ambulatory Care** |
| **Net operating revenues** | $**4048** | $**1320** |
| **Revenue from contract termination** | **413** | **—** |
| **Equity in earnings of unconsolidated affiliates** | **—** | **51** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 1844 | 330 |
| &nbsp;&nbsp;&nbsp;Supplies | 604 | 357 |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 922 | 200 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 188 | 41 |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 12 | 12 |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 14 | 13 |
| &nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities |  | (1) |
| **Operating income** | $**877** | $**419** |
| **Net operating revenues** | **100.0%** | **100.0%** |
| **Revenue from contract termination** | **10.2%** | **— %** |
| **Equity in earnings of unconsolidated affiliates** | **— %** | **3.9%** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 45.6% | 25.0% |
| &nbsp;&nbsp;&nbsp;Supplies | 14.9% | 27.1% |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 22.8% | 15.2% |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 4.6% | 3.1% |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 0.3% | 0.9% |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 0.3% | 1.0% |
| &nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities | —% | (0.1)% |
| **Operating income** | **21.7%** | **31.7%** |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **Hospital Operations** | **Ambulatory Care** |
| **Net operating revenues** | $**4029** | $**1194** |
| **Equity in earnings of unconsolidated affiliates** | **2** | **54** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 1824 | 295 |
| &nbsp;&nbsp;&nbsp;Supplies | 589 | 318 |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 911 | 179 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 167 | 39 |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 9 | 10 |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 17 |  |
| &nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities | (10) | (12) |
| **Operating income** | $**524** | $**419** |
| **Net operating revenues** | **100.0%** | **100.0%** |
| **Equity in earnings of unconsolidated affiliates** | **— %** | **4.5%** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;Salaries, wages and benefits | 45.3% | 24.7% |
| &nbsp;&nbsp;&nbsp;Supplies | 14.6% | 26.6% |
| &nbsp;&nbsp;&nbsp;Other operating expenses, net | 22.6% | 15.0% |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 4.1% | 3.3% |
| &nbsp;&nbsp;&nbsp;Impairment and restructuring charges, and acquisition-related costs | 0.2% | 0.8% |
| &nbsp;&nbsp;&nbsp;Litigation and investigation costs | 0.4% | —% |
| &nbsp;&nbsp;Net gains on sales, consolidation and deconsolidation of facilities | (0.2)% | (1.0)% |
| **Operating income** | **13.0%** | **35.1%** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**RESULTS OF OPERATIONS BY SEGMENT**

**Hospital Operations Segment**

The following tables present operating statistics, revenues and expenses of our hospitals and related outpatient facilities on a same-hospital basis, unless otherwise indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Same-Hospital** | **Same-Hospital** | | |
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** | **Increase<br>(Decrease)** |
|<br>**Admissions, Patient Days and Surgeries** | **2026** | **2025** | **Increase<br>(Decrease)** | **Increase<br>(Decrease)** |
| Number of hospitals | 49 | 49 |  | (1) |
| Total admissions | 120375 | 120090 | 0.2% |  |
| Adjusted admissions | 214225 | 213039 | 0.6% |  |
| Paying admissions (excludes charity and uninsured) | 115109 | 115289 | (0.2)% |  |
| Charity and uninsured admissions | 5266 | 4801 | 9.7% |  |
| Admissions through emergency department | 91713 | 91386 | 0.4% |  |
| Paying admissions as a percentage of total admissions | 95.6% | 96.0% | (0.4)% | (1) |
| Charity and uninsured admissions as a percentage of total admissions | 4.4% | 4.0% | 0.4% | (1) |
| Emergency department admissions as a percentage of total admissions | 76.2% | 76.1% | 0.1% | (1) |
| Surgeries — inpatient | 29092 | 29533 | (1.5)% |  |
| Surgeries — outpatient | 36590 | 36722 | (0.4)% |  |
| Total surgeries | 65682 | 66255 | (0.9)% |  |
| Patient days — total | 597974 | 605785 | (1.3)% |  |
| Adjusted patient days | 1021525 | 1036716 | (1.5)% |  |
| Average length of stay (days) | 4.97 | 5.04 | (1.4)% |  |
| Licensed beds (at end of period) | 12445 | 12435 | 0.1% |  |
| Average licensed beds | 12445 | 12435 | 0.1% |  |
| Utilization of licensed beds | 53.4% | 54.1% | (0.7)% | (1) |

---

(1) The change is the difference between the 2026 and 2025 amounts or percentages presented.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Same-Hospital** | **Same-Hospital** | | |
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** | **Increase<br>(Decrease)** |
|<br>**Outpatient Visits** | **2026** | **2025** | **Increase<br>(Decrease)** | **Increase<br>(Decrease)** |
| Total visits | 1349093 | 1400822 | (3.7)% |  |
| Paying visits (excludes charity and uninsured) | 1247782 | 1306179 | (4.5)% |  |
| Charity and uninsured visits | 101311 | 94643 | 7.0% |  |
| Emergency department visits | 456100 | 474620 | (3.9)% |  |
| Surgery visits | 36590 | 36722 | (0.4)% |  |
| Paying visits as a percentage of total visits | 92.5% | 93.2% | (0.7)% | (1) |
| Charity and uninsured visits as a percentage of total visits | 7.5% | 6.8% | 0.7% | (1) |

---

(1) The change is the difference between the 2026 and 2025 percentages presented.

---

| | | | |
|:---|:---|:---|:---|
| | **Same-Hospital** | **Same-Hospital** | |
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** |
|<br>**Revenues** | **2026** | **2025** | **Increase<br>(Decrease)** |
| Total segment net operating revenues | $4030 | $4024 | 0.1% |
| **Selected revenue data – hospitals and related outpatient facilities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net patient service revenues | $3458 | $3491 | (0.9)% |
| &nbsp;&nbsp;&nbsp;Net patient service revenue per adjusted admission | $16142 | $16387 | (1.5)% |
| &nbsp;&nbsp;&nbsp;Net patient service revenue per adjusted patient day | $3385 | $3367 | 0.5% |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Same-Hospital** | **Same-Hospital** | |
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** |
|<br>**Selected Operating Expenses** | **2026** | **2025** | **Increase<br>(Decrease)** |
| Salaries, wages and benefits | $1837 | $1826 | 0.6% |
| Supplies | 603 | 589 | 2.4% |
| Other operating expenses, net | 912 | 888 | 2.7% |
|  | $**3352** | $**3303** | **1.5%** |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **Same-Hospital** | **Same-Hospital** | |
| **Selected Operating Expenses as a Percentage of Net Operating Revenues** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase**<br>**(Decrease)(1)** |
| **Selected Operating Expenses as a Percentage of Net Operating Revenues** | **2026** | **2025** | **Increase**<br>**(Decrease)(1)** |
| Salaries, wages and benefits | 45.6% | 45.4% | 0.2% |
| Supplies | 15.0% | 14.6% | 0.4% |
| Other operating expenses, net | 22.6% | 22.1% | 0.5% |

---

(1) The change is the difference between the 2026 and 2025 percentages presented.

*Revenues*

Same-hospital net operating revenues increased by $6 million, or 0.1%, during the three months ended March 31, 2026 compared to the three months ended March 31, 2025. This increase was primarily attributable to higher patient volumes, partially offset by a less favorable payer mix during the 2026 period.

*Salaries, Wages and Benefits*

Same-hospital salaries, wages and benefits expense increased by $11 million, or 0.6%, in the three months ended March 31, 2026 compared to the same period in 2025. This change was primarily attributable to higher employee benefits costs and annual merit increases for certain of our employees. These factors were partially offset by lower incentive compensation expense, contract labor costs and premium pay during the 2026 period. Same-hospital salaries, wages and benefits expense as a percentage of net operating revenues increased by 20 basis points to 45.6% in the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

*Supplies*

Same-hospital supplies expense increased by $14 million, or 2.4%, in the three months ended March 31, 2026 compared to the same period in 2025. This increase was driven by higher patient volumes during the 2026 period, partially offset by our cost-efficiency measures. Same-hospital supplies expense as a percentage of net operating revenues increased from 14.6% for the three months ended March 31, 2025 to 15.0% for the three months ended March 31, 2026.

*Other Operating Expenses, Net*

Same-hospital other operating expenses increased by $24 million, or 2.7%, in the three months ended March 31, 2026 compared to the same period in 2025. This increase was primarily attributable to an increase in medical fees, as well as higher professional and consulting costs, partially offset by a decrease in malpractice expense during the 2026 period. Same-hospital other operating expenses as a percentage of net operating revenues increased by 50 basis points to 22.6% for the three months ended March 31, 2026 compared to 22.1% for the three months ended March 31, 2025.

**Ambulatory Care Segment**

The following table presents selected revenue and expense information for our Ambulatory Care segment:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase<br>(Decrease)** |
| | **2026** | **2025** | **Increase<br>(Decrease)** |
| Net operating revenues | $1320 | $1194 | 10.6% |
| Equity in earnings of unconsolidated affiliates | $51 | $54 | (5.6)% |
| Salaries, wages and benefits | $330 | $295 | 11.9% |
| Supplies | $357 | $318 | 12.3% |
| Other operating expenses, net | $200 | $179 | 11.7% |

---

*Revenues*

Our Ambulatory Care segment's net operating revenues increased by $126 million, or 10.6%, during the three months ended March 31, 2026 compared to the same period in 2025. The change was driven by (1) a $77 million increase from 2025 and 2026 acquisitions, de novo development and purchases of controlling interests, partially offset by the impact of the closure and sale of certain facilities, and (2) a $49 million increase in same-facility net operating revenues, which was primarily attributable to incremental revenue from negotiated commercial rate increases, higher patient acuity and the addition of new service lines.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

*Salaries, Wages and Benefits*

Salaries, wages and benefits expense increased by $35 million, or 11.9%, during the three months ended March 31, 2026 compared to the same period in 2025. This change was driven by (1) an $18 million increase from our 2025 and 2026 acquisitions, de novo development and purchases of controlling interests, partially offset by the impact of the closure and sale of certain facilities, and (2) an increase of $17 million in same-facility salaries, wages and benefits expense. As a percentage of net operating revenues, salaries, wages and benefits expense increased to 25.0% for the three months ended March 31, 2026 from 24.7% for the same period in 2025.

*Supplies*

Supplies expense increased by $39 million, or 12.3%, during the three months ended March 31, 2026 compared to the same period in 2025. The change was driven by (1) a $27 million increase related to our 2025 and 2026 acquisitions, de novo development and purchases of controlling interests, partially offset by the impact of the closure and sale of certain facilities, and (2) a $12 million increase in same-facility supplies expense, due primarily to higher patient acuity and the addition of new service lines. Supplies expense as a percentage of net operating revenues increased to 27.1% for the three months ended March 31, 2026 from 26.6% for the same period in 2025.

*Other Operating Expenses, Net*

Other operating expenses increased by $21 million, or 11.7%, during the three months ended March 31, 2026 compared to the same period in 2025. The change was driven by (1) a $15 million increase from our 2025 and 2026 acquisitions, de novo development and purchases of controlling interests, partially offset by the impact of the closure and sale of certain facilities, and (2) a $6 million increase in same-facility other operating expenses. Other operating expenses as a percentage of net operating revenues increased to 15.2% for the three months ended March 31, 2026 from 15.0% for the same period in 2025.

*Facility Growth*

The following table presents the year-over-year changes in our revenue and cases on a same-facility systemwide basis:

---

| | |
|:---|:---|
| | **Three Months Ended<br>March 31, 2026** |
| Net revenues | 5.3% |
| Cases | (0.3)% |
| Net revenue per case | 5.6% |

---

*Facility Acquisitions and Investment*

The table below presents the aggregate cash activity related to our acquisition of various ownership interests in ambulatory care facilities:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Purchases of controlling interests | $120 | $17 |
| Acquisition-related cash adjustments | 1 | 10 |
| Equity investment in unconsolidated affiliates and consolidated facilities that did not result in a change of control | 4 | 9 |
|  | $**125** | $**36** |

---

During the three months ended March 31, 2026, our Ambulatory Care segment paid an aggregate of $120 million to acquire controlling ownership interests in seven ASCs. In the same period, this segment also commenced operations at three de novo ASCs and ceased operations at two ASCs.

**Consolidated**

*Gains and Losses on Sales, Consolidation and Deconsolidation of Facilities*

We recorded net gains from the sale, consolidation and deconsolidation of facilities totaling $1 million during the three months ended March 31, 2026. We recorded gains from the sale, consolidation and deconsolidation of facilities totaling $22 million during the three months ended March 31, 2025, primarily comprised of gains related to post-closing adjustments from the 2024 divestiture of five hospitals and certain related operations located in Alabama and the consolidation of certain Ambulatory Care segment facilities.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

*Income Tax Expense*

A reconciliation between the amount of reported income tax expense and the amount computed by multiplying income before income taxes by the statutory federal tax rate is presented below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| | **Amount** | **Percent** | **Amount** | **Percent** |
| Tax expense at statutory federal rate | $238 | 21.0% | $161 | 21.0% |
| Domestic federal tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Nontaxable or nondeductible items: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax benefit attributable to noncontrolling interests | (43) | (3.8)% | (44) | (5.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 6 | 0.6% | 1 | 0.1% |
| &nbsp;&nbsp;Stock-based compensation tax benefit | (14) | (1.2)% | (4) | (0.5)% |
| &nbsp;&nbsp;State and local income taxes, net of federal income tax effect | 41 | 3.6% | 31 | 4.1% |
| Changes in valuation allowances | (3) | (0.3)% | (2) | (0.3)% |
| Changes in prior year unrecognized tax benefits | 1 | 0.1% |  | —% |
| &nbsp;&nbsp;&nbsp;**Income tax expense** | $**226** | **20.0%** | $**143** | **18.7%** |

---

Income before income taxes for the three months ended March 31, 2026 and 2025 was $1.132 billion and $765 million, respectively. The change in our valuation allowance during the three months ended March 31, 2026 was related to state interest expense limitations and changes in the realizability of deferred tax assets. The decrease in our valuation allowance during the three months ended March 31, 2025 was related to interest expense limitations and changes in the realizability of deferred tax assets.

*Net Income Available to Noncontrolling Interests*

The table below presents net income available to noncontrolling interests by segment for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Hospital Operations | $11 | $39 |
| Ambulatory Care | 193 | 177 |
| **Total net income available to noncontrolling interests** | $**204** | $**216** |

---

**LIQUIDITY AND CAPITAL RESOURCES**

***CASH REQUIREMENTS***

There have been no material changes to our obligations to make future cash payments under scheduled contractual obligations, such as debt and lease agreements, and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the matters set forth below and the additional lease obligations disclosed in Note 1 to our accompanying Condensed Consolidated Financial Statements.

**Long-Term Debt**

Interest payments, net of capitalized interest, were $24 million and $99 million in the three months ended March 31, 2026 and 2025, respectively.

**Other Cash Requirements**

Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations); surgical hospital expansion focused on higher-acuity services; equipment and information systems additions and replacements; introduction of new medical technologies (including robotics); design and construction of new facilities; and various other capital improvements. Capital expenditures were $180 million and $173 million in the three months ended March 31, 2026 and 2025, respectively. We anticipate that our capital expenditures for the year ending December 31, 2026 will total approximately $700 million to $800 million, including $111 million that was accrued as a liability at December 31, 2025.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

***SOURCES AND USES OF CASH***

Our liquidity for the three months ended March 31, 2026 was primarily derived from net cash provided by operating activities and cash on hand. Our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions, due to shifts in payer mix and other factors. Our Credit Agreement provides additional liquidity to manage fluctuations in operating cash caused by these factors.

Net cash provided by operating activities was $1.641 billion in the three months ended March 31, 2026 compared to $815 million in the three months ended March 31, 2025. Key factors contributing to the change between the 2026 and 2025 periods included the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contract termination payments received of $540 million in the 2026 period;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Interest payments that were $75 million lower in the 2026 period; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The timing of working capital items.

Net cash used in investing activities was $317 million during the three months ended March 31, 2026 compared to $187 million during the three months ended March 31, 2025. The primary factor contributing to the change between the 2026 and 2025 periods was a $94 million increase in payments for purchases of businesses or joint venture interests in the 2026 period.

Net cash used in financing activities was $1.240 billion and $648 million during the three months ended March 31, 2026 and 2025, respectively. The primary factor contributing to the change between the 2026 and 2025 periods was Conifer's redemption of CHI's minority equity interest effective January 1, 2026, which transaction was the primary driver of payments totaling $549 million for purchases of noncontrolling interests in the 2026 period, an increase of $508 million over the 2025 period.

***DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS***

*Credit Agreement—*At March 31, 2026, our Credit Agreement provided for revolving loans in an aggregate principal amount of up to $1.900 billion with a $200 million subfacility for standby letters of credit. At March 31, 2026, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible accounts receivable, eligible inventory and Medicaid supplemental payments, $1.900 billion was available for borrowing under the Credit Agreement at March 31, 2026. We were in compliance with all covenants and conditions in our Credit Agreement at March 31, 2026.

*Letter of Credit Facility—*We have a letter of credit facility (as amended to date, the "LC Facility") that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200 million. At March 31, 2026, we were in compliance with all covenants and conditions in the LC Facility, and we had $104 million of standby letters of credit outstanding thereunder.

*Senior Unsecured Notes and Senior Secured Notes—*At March 31, 2026, we had outstanding senior unsecured notes and senior secured notes with aggregate principal amounts outstanding of $12.662 billion. These notes have fixed interest rates and require semi-annual interest payments in arrears. The principal and any accrued but unpaid interest is due upon the maturity date of the respective notes, which dates are staggered from November 2027 through November 2033.

For additional information regarding our long-term debt, see Note 5 to the accompanying Condensed Consolidated Financial Statements and Note 8 to the Consolidated Financial Statements included in our Annual Report.

***LIQUIDITY***

From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.

Our cash on hand fluctuates day-to-day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest payments and income tax payments. These fluctuations can result in material intra-quarter net operating and investing uses of cash that have caused, and in the future may cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, borrowing availability under our Credit Agreement and anticipated future cash provided by our operating activities are adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

incurrence, are adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to current and former joint venture partners, and other presently known operating needs.

Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual or regulatory commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected should there be a deterioration in our results of operations, including our ability to generate sufficient cash from operations, as well as by the various risks and uncertainties discussed in this section, and the Risk Factors section in Part I of our Annual Report, including changes in federal and state statutes, regulations and executive orders that effect the healthcare industry directly or indirectly, particularly those impacting government healthcare funding, and significant costs associated with legal proceedings and government investigations.

We have not relied on commercial paper or other short-term financing arrangements or entered into repurchase agreements or other short-term financing arrangements not otherwise reported in our balance sheet. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest except for borrowings, if any, under our Credit Agreement.

**CRITICAL ACCOUNTING ESTIMATES**

In preparing our Condensed Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions. Our critical accounting estimates cover the following areas:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Recognition of net operating revenues, including contractual allowances and implicit price concessions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Accruals for general and professional liability risks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Impairment of long-lived assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Impairment of goodwill; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Accounting for income taxes.

Additional discussion of our critical accounting estimates is provided in our Annual Report.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The following table presents information about certain of our market-sensitive financial instruments at March 31, 2026. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the end of the reporting period. The effects of unamortized discounts and issue costs are excluded from the table.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Maturity Date, Years Ending December 31,** | **Maturity Date, Years Ending December 31,** | **Maturity Date, Years Ending December 31,** | **Maturity Date, Years Ending December 31,** | **Maturity Date, Years Ending December 31,** | | | |
| | **2026** | **2027** | **2028** | **2029** | **2030** |<br>**Thereafter** |<br>**Total** |<br>**Fair Value** |
| | **(Dollars in Millions)** | **(Dollars in Millions)** | **(Dollars in Millions)** | **(Dollars in Millions)** | **(Dollars in Millions)** | **(Dollars in Millions)** | **(Dollars in Millions)** | **(Dollars in Millions)** |
| Fixed-rate long-term debt | $61 | $1634 | $2412 | $1445 | $3473 | $4273 | $13298 | $13158 |
| Average effective interest rates | 8.0% | 5.4% | 5.8% | 4.4% | 5.4% | 6.4% | 5.7% |  |

---

We have no affiliation with partnerships, trusts or other entities (sometimes referred to as "special-purpose" or "variable-interest" entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities. We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**ITEM 4. CONTROLS AND PROCEDURES**

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective as of March 31, 2026 to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

Because we provide healthcare services in a highly regulated industry, we have been and expect to continue to be party to various lawsuits, claims and regulatory investigations from time to time. For information regarding material legal proceedings in which we are involved, see Note 11 to our accompanying Condensed Consolidated Financial Statements, which is incorporated by reference.

**ITEM 1A. RISK FACTORS**

There have been no material changes to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2025.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The table below presents share repurchase transactions completed during the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Program(1)** | **Maximum Dollar Value of Shares That May Yet Be Purchased Under the Program** |
| | **(In Thousands)** | | **(In Thousands)** | **(In Millions)** |
| January 1 through January 31, 2026 |  | $— |  | $1490 |
| February 1 through February 28, 2026 |  | $— |  | $1490 |
| March 1 through March 31, 2026 | 1346 | $236.30 | 1346 | $1172 |

---

(1) In July 2024, our board of directors authorized the repurchase of up to $1.500 billion of our common stock through a share repurchase program that has no expiration date. In July 2025, the board authorized a $1.500 billion increase to the program. The share repurchase program does not obligate us to acquire any particular amount of common stock, and it may be suspended for periods or discontinued at any time.

These repurchases were made, and any future repurchases will be made, in open-market or privately negotiated transactions, at management's discretion subject to market conditions and other factors, and in a manner consistent with applicable securities laws and regulations.

The table does not include shares tendered to satisfy the exercise price in connection with cashless exercises of employee stock options or shares tendered to satisfy tax withholding obligations in connection with employee or director equity awards.

**ITEM 5. OTHER INFORMATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Trading Plans**

During the three months ended March 31, 2026, none of our directors or Section 16 officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408 of the SEC's Regulation S-K.

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**ITEM 6. EXHIBITS** 

Unless otherwise indicated, the following exhibits are filed (or, in the case of Exhibit 32, furnished) with this report:

---

| | | |
|:---|:---|:---|
| (10) | Material Contracts | Material Contracts |
|  | (a) | <u>[Retirement Transition Agreement and General Release by and among the Registrant and Paola Arbour, dated April 9, 2026 (Incorporated by reference to Exhibit 10.1 to Registrant's Current Report on Form 8-K filed April 10, 2026)\*](https://www.sec.gov/Archives/edgar/data/70318/000007031826000019/thc-20260409ex101.htm)</u> |
| (31) | Rule 13a-14(a)/15d-14(a) Certifications | Rule 13a-14(a)/15d-14(a) Certifications |
|  | (a) | <u>[Certification of Saumya Sutaria, M.D., Chief Executive Officer](thc-20260331x10qxex31a.htm)</u> |
|  | (b) | <u>[Certification of Sun Park, Executive Vice President and Chief Financial Officer](thc-20260331x10qex31b.htm)</u> |
| (32) | <u>[Section 1350 Certifications of Saumya Sutaria, M.D., Chief Executive Officer, and Sun Park, Executive Vice President and Chief Financial Officer](thc-20260331x10qxex32.htm)</u> | <u>[Section 1350 Certifications of Saumya Sutaria, M.D., Chief Executive Officer, and Sun Park, Executive Vice President and Chief Financial Officer](thc-20260331x10qxex32.htm)</u> |
| (101 SCH) | Inline XBRL Taxonomy Extension Schema Document | Inline XBRL Taxonomy Extension Schema Document |
| (101 CAL) | Inline XBRL Taxonomy Extension Calculation Linkbase Document | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| (101 DEF) | Inline XBRL Taxonomy Extension Definition Linkbase Document | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| (101 LAB) | Inline XBRL Taxonomy Extension Label Linkbase Document | Inline XBRL Taxonomy Extension Label Linkbase Document |
| (101 PRE) | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| (101 INS) | Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document | Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document |
| (104) | Cover page from the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 formatted in Inline XBRL (included in Exhibit 101) | Cover page from the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 formatted in Inline XBRL (included in Exhibit 101) |
| \* Management contract or compensatory plan or arrangement | \* Management contract or compensatory plan or arrangement | \* Management contract or compensatory plan or arrangement |

---

------

<u>[**Table of Contents**](#i7edabb704b8149fc98557a0e4d1fc5ff_10)</u>

**SIGNATURES**

&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | TENET HEALTHCARE CORPORATION<br>(Registrant) |
| Date: April 30, 2026 | By: | /s/ R. SCOTT RAMSEY |
|  |  | R. Scott Ramsey |
|  |  | Senior Vice President, Controller |
|  |  | *(Principal Accounting Officer)* |

---

## Ex-31.A

**Exhibit 31(a)**

**Rule 13a-14(a)/15d-14(a) Certification**

I, Saumya Sutaria, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of Tenet Healthcare Corporation (the "Registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: April 30, 2026 | /s/ SAUMYA SUTARIA |
| | Saumya Sutaria, M.D. |
| | *Chief Executive Officer* |

---

## Ex-31.B

**Exhibit 31(b)**

**Rule 13a-14(a)/15d-14(a) Certification**

I, Sun Park, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this quarterly report on Form 10-Q of Tenet Healthcare Corporation (the "Registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: April 30, 2026 | /s/ SUN PARK |
| | Sun Park |
| | *Executive Vice President and Chief Financial Officer* |

---

## Ex-32

**Exhibit 32**

**Certifications Pursuant to Section 1350 of Chapter 63 <br>of Title 18 of the United States Code**

We, the undersigned Saumya Sutaria and Sun Park, being, respectively, the Chief Executive Officer and the Executive Vice President and Chief Financial Officer of Tenet Healthcare Corporation (the "Registrant"), do each hereby certify that (i) the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "Form 10-Q"), to be filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Registrant and its subsidiaries.

---

| | |
|:---|:---|
| Date: April 30, 2026 | /s/ SAUMYA SUTARIA |
| | Saumya Sutaria, M.D. |
| | *Chief Executive Officer* |
| Date: April 30, 2026 | /s/ SUN PARK |
| | Sun Park |
| | *Executive Vice President and Chief Financial Officer* |

---

The foregoing certification is being furnished solely pursuant to 18 U.S.C. §1350; it is not being filed for purposes of Section 18 of the Securities Exchange Act, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

<br>